≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Malignant neoplasm of penis, including Hilmo

Endpoint Browser PheWeb

C3_PENIS_WIDE

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

only males

226725

2. Check conditions

None

226725

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — C60
  • Hospital discharge: ICD-9 — 187[1-4]
  • Hospital discharge: ICD-8 — 1870
  • Cause of death: ICD-10 — C60
  • Cause of death: ICD-9 — 187[1-4]
  • Cause of death: ICD-8 — 1870
  • Cancer registry: Topography ICD-O-3 — C60
  • Cancer registry: Morphology ICD-O-3 — ANY
  • Cancer registry: Behaviour codes — 3

3 out of 7 registries used, show all original rules.

236

4. Check minimum number of events

None

236

5. Include endpoints

None

236

6. Filter based on genotype QC (FinnGen only)

226

Control definitions (FinnGen only)

Control exclude
C3_CANCER, C3_CANCER_WIDE

Extra metadata

First used in FinnGen datafreeze
DF12

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

This endpoint is excluded (different definition than used in FinnGen).

-FinnGen-

Key figures

All Female Male
Number of individuals 226 - 226
Unadjusted period prevalence (%) 0.10 - 0.10
Median age at first event (years) 67.50 - 67.50

-FinnGen-

Age distribution of first events

-FinnGen-

Year distribution of first events

-FinnGen-

Cumulative Incidence Function

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
236
Matched controls
2360
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
C60.1
ICD-10 Finland
Malignant neoplasm: Glans penis
+∞
149.3
127
*
C60.9
ICD-10 Finland
Malignant neoplasm: Penis, unspecified
+∞
111.5
98
*
C61
ICD-10 Finland
Malignant neoplasm of prostate
1242.0
89.9
82
*
8140/3-C61.9
ICD-O-3
Adenocarcinoma, NOS, of prostate gland
+∞
85.8
77
*
C60.0
ICD-10 Finland
Malignant neoplasm: Prepuce
+∞
83.4
75
*
JA1AE
NOMESCO Finland
Ultrasound examination of groin and abdominal wall
39.4
78.7
50
16
PJA12
NOMESCO Finland
Sentinel node biopsy
+∞
71.6
65
*
JN4AD
NOMESCO Finland
Body CT examination
13.2
62.1
68
70
116
Kela drug reimbursment
Prostate cancer
+∞
61.1
56
*
8070/3-C60.9
ICD-O-3
Squamous cell carcinoma, NOS, of penis, NOS
+∞
56.6
52
*
KGC00
NOMESCO Finland
Partial amputation of penis
+∞
55.4
51
*
KGH10
NOMESCO Finland
Operation for phimosis
13.2
55.2
59
58
KGB00
NOMESCO Finland
Biopsy of penis
331.5
53.5
52
*
130
Kela drug reimbursment
Malignant tumour
+∞
52.0
48
*
PJD55
NOMESCO Finland
Block dissection of inguinal lymph nodes
+∞
47.5
44
*
JN4BD
NOMESCO Finland
Extensive body CT
11.8
45.9
52
55
N48.1
ICD-10 Finland
Balanoposthitis
13.7
44.5
45
40
D40.7
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Other male genital organs
+∞
44.2
41
*
A03FA01
ATC
metoclopramide; systemic, rectal
9.1
43.4
62
89
L02AE02
ATC
leuprorelin; implant, parenteral
+∞
41.9
39
*
8070/3-C60.1
ICD-O-3
Squamous cell carcinoma, NOS, of glans penis
+∞
40.8
38
*
N47
ICD-10 Finland
Redundant prepuce, phimosis and paraphimosis
9.8
40.0
52
66
KGD00
NOMESCO Finland
Partial excision of glans penis
+∞
37.5
35
*
H02AB02
ATC
dexamethasone; systemic
58.0
37.1
43
9
UKC02
NOMESCO Finland
Cystoscopy
5.7
36.6
98
263
WX402
NOMESCO Finland
General anaesthesia
5.9
36.1
88
217
L02BB03
ATC
bicalutamide; oral
+∞
35.3
33
*
Z51.5
ICD-10 Finland
Palliative care
9.4
32.2
42
53
ZZA00
NOMESCO Finland
Split skin graft
13.6
31.4
31
26
WF002
NOMESCO Finland
Radical radiotherapy
+∞
29.8
28
*
XX3DW
NOMESCO Finland
Time consuming IT work
10.2
29.7
36
41
PJ5AQ
NOMESCO Finland
Sentinell lymphnode SPECT with low dose CT
+∞
28.7
27
*
Y77
ICPC
Malignant neoplasm prostate
+∞
27.6
26
*
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
+∞
25.5
24
*
KGD96
NOMESCO Finland
Other partial excision of penis
+∞
25.5
24
*
KGD05
NOMESCO Finland
Partial excision of body of penis
+∞
24.4
23
*
C60.2
ICD-10 Finland
Malignant neoplasm: Body of penis
+∞
24.4
23
*
XKD00
NOMESCO Finland
Uroflowmetry
4.0
23.0
93
328
KC1EE
NOMESCO Finland
Ultrasound measurement of residual urine
4.1
22.7
86
289
A04AA02
ATC
granisetron; systemic, transdermal
+∞
22.2
21
*
WF049
NOMESCO Finland
Radiotherapy of metastasis
241.4
22.0
22
*
T81.4
ICD-10 Finland
Infection following a procedure, not elsewhere classified
5.5
21.9
48
104
WZC00
NOMESCO Finland
Treatment plan or consultation
3.9
21.8
93
339
KE1AT
NOMESCO Finland
Biopsy of prostata with ultrasoudnguidance
7.5
21.5
33
50
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
+∞
21.2
20
*
C60.8
ICD-10 Finland
Malignant neoplasm: Overlapping lesion of penis
+∞
21.2
20
*
B01AB10
ATC
tinzaparin; parenteral
6.5
21.1
38
68
C77.4
ICD-10 Finland
Secondary and unspecified malignant neoplasm: Inguinal and lower limb lymph nodes
+∞
20.1
19
*
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
20.1
19
*
PJD54
NOMESCO Finland
Block dissection of iliac lymph nodes
+∞
20.1
19
*
WX408
NOMESCO Finland
General anesthesy, balanced
3.8
20.0
82
288
R74.8
ICD-10 Finland
Abnormal levels of other serum enzymes
6.4
19.8
36
65
YL1BD
NOMESCO Finland
Extensive CT examination of pelvis for dose design of radiotherapy
+∞
17.9
17
*
WF003
NOMESCO Finland
Adjuvant radiotherapy
+∞
17.9
17
*
N02AA05
ATC
oxycodone; systemic
3.9
17.1
61
193
D07.4
ICD-10 Finland
Carcinoma in situ: Penis
182.4
16.7
17
*
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
182.4
16.7
17
*
JN3BD
NOMESCO Finland
Extensive abdominal CT
5.0
16.4
39
90
JN2AE
NOMESCO Finland
Ultrasound examination of lower part of abdomen without contrast
23.0
16.3
23
11
ZXE10
NOMESCO Finland
More than one and less than three hours
3.1
15.9
103
471
WZC30
NOMESCO Finland
Teaching
3.9
15.8
55
170
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
5.3
15.7
34
72
TKD00
NOMESCO Finland
Dilatation of urethra
41.1
15.6
19
5
163
Kela drug reimbursment
Abiraterone and enzalutamide
+∞
14.7
14
*
KGC10
NOMESCO Finland
Total amputation of penis
+∞
14.7
14
*
NK6AN
NOMESCO Finland
Total body bone isotope imaging
+∞
14.7
14
*
WX240
NOMESCO Finland
Penis blockade
29.3
14.5
19
7
8090/3-C44.9
ICD-O-3
Basal cell carcinoma, NOS, of skin, NOS
+∞
13.7
13
*
C78.0
ICD-10 Finland
Secondary malignant neoplasm of lung
+∞
13.7
13
*
A04AA01
ATC
ondansetron; systemic, rectal
16.3
13.4
21
14
L02BB04
ATC
enzalutamide; oral
+∞
12.6
12
*
C79.5
ICD-10 Finland
Secondary malignant neoplasm of bone and bone marrow
+∞
12.6
12
*
308
Kela drug reimbursment
Alprostadil, sildenafil and combination product containing aviptadil and phentolamine
+∞
12.6
12
*
J01MA02
ATC
ciprofloxacin; systemic
2.7
12.5
117
632
B01AB05
ATC
enoxaparin; parenteral
2.8
12.1
83
382
KDH10
NOMESCO Finland
Meatoplasty of urethra
49.3
12.0
14
*
QX2XE
NOMESCO Finland
Ultrsound examination of soft tissue not elsewhere classified
10.9
11.8
22
22
R33
ICD-10 Finland
Retention of urine
3.3
11.7
52
187
C60
ICD-10 Finland
Malignant neoplasm of penis
+∞
11.5
11
*
PJD45
NOMESCO Finland
Excision of inguinal lymph nodes
125.9
11.5
12
*
L03AA13
ATC
pegfilgrastim; parenteral
125.9
11.5
12
*
L03AA02
ATC
filgrastim; parenteral
125.9
11.5
12
*
YL1AD
NOMESCO Finland
CT examination of pelvis for dose design of radiotherapy
125.9
11.5
12
*
J01EA01
ATC
trimethoprim; systemic
3.4
11.4
47
161
KGD10
NOMESCO Finland
Destruction of lesion of penis
37.0
11.4
14
*
L90.0
ICD-10 Finland
Lichen sclerosus et atrophicus
18.2
11.4
17
10
N48.9
ICD-10 Finland
Disorder of penis, unspecified
45.6
11.0
13
*
C44.31
ICD-10 Finland
Basocellular carcinoma of the skin on another or unspecified part of the face
45.6
11.0
13
*
ZX120
NOMESCO Finland
Intravenous
4.4
10.8
29
73
J01DB01
ATC
cefalexin; oral
3.3
10.7
199
1466
QBE10
NOMESCO Finland
Excision of other lesion extending through all layers of skin of trunk
5.8
10.6
20
37
WX320
NOMESCO Finland
Spinalanesthesy
2.7
10.6
75
348
L01BC06
ATC
capecitabine; oral
+∞
10.5
10
*
WB113
NOMESCO Finland
Multiple adjuvant cytostatic therapy
+∞
10.5
10
*
WB103
NOMESCO Finland
Simple adjuvant cytostatic therapy
+∞
10.5
10
*
8070/3-C60.0
ICD-O-3
Squamous cell carcinoma, NOS, of prepuce
+∞
10.5
10
*
ZX070
NOMESCO Finland
Intensity modified radiotherapy
+∞
10.5
10
*
PJ5AN
NOMESCO Finland
Localisation of sentinell lymphnode with isotope imaging
+∞
10.5
10
*
TKC20
NOMESCO Finland
Catheterisation of bladder
3.8
10.3
34
100
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
3.4
10.2
41
138
D29.0
ICD-10 Finland
Benign neoplasm: Penis
+∞
9.4
9
*
C78.7
ICD-10 Finland
Secondary malignant neoplasm of liver and intrahepatic bile duct
+∞
9.4
9
*
WD405
NOMESCO Finland
Simple antiboidy therapy of methastized malignancy
+∞
9.4
9
*
L03AA14
ATC
lipegfilgrastim; parenteral
+∞
9.4
9
*
KEC01
NOMESCO Finland
Percutaneous endoscopic radical prostatectomy
+∞
9.4
9
*
8120/3-C67.9
ICD-O-3
Transitional cell carcinoma, NOS, of bladder, NOS
+∞
9.4
9
*
L02BX02
ATC
degarelix; parenteral
+∞
9.4
9
*
A04AD12
ATC
aprepitant; systemic
+∞
9.4
9
*
PJ2AT
NOMESCO Finland
Biopsy of lymphnode with ultrasound guidance
+∞
9.4
9
*
C67.8
ICD-10 Finland
Malignant neoplasm: Overlapping lesion of bladder
+∞
9.4
9
*
JN4CD
NOMESCO Finland
Very extensive body CT
14.5
9.3
15
11
A49.9
ICD-10 Finland
Bacterial infection, unspecified
3.0
9.2
45
170
G04BE03
ATC
sildenafil; oral
38.3
9.1
11
*
KCD02
NOMESCO Finland
Transurethral resection of bladder
25.2
9.0
12
5
TPH07
NOMESCO Finland
Cathetrisation of artery
3.1
8.9
40
144
N48.8
ICD-10 Finland
Other specified disorders of penis
14.8
8.8
14
10
QBB10
NOMESCO Finland
Major dressing of wound of skin of trunk
8.8
8.8
18
22
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
52.0
8.7
10
*
WX602
NOMESCO Finland
Repeated or continuing anesthesia shots throug a catheter
6.9
8.7
21
33
ZXC96
NOMESCO Finland
Robot assisted procedure
93.3
8.5
9
*
C67.9
ICD-10 Finland
Malignant neoplasm: Bladder, unspecified
93.3
8.5
9
*
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
2.9
8.4
45
178
JN2DG
NOMESCO Finland
Very extensive MRI examination of lower part of abdoment with high intensity magnet
+∞
8.4
8
*
352
Kela drug reimbursment
Abiraterone and enzalutamide
+∞
8.4
8
*
L02BX03
ATC
abiraterone; oral
+∞
8.4
8
*
WD225
NOMESCO Finland
Demanding therapy of methastized malignancy with hormones
+∞
8.4
8
*
PJD64
NOMESCO Finland
Laparoscopic dissection of iliac lymph nodes
+∞
8.4
8
*
YJ2VG
NOMESCO Finland
MRI examination of pelvis with high intensity magnet for dose design of radiotherapy
+∞
8.4
8
*
KEC00
NOMESCO Finland
Retropubic radical prostatectomy
+∞
8.4
8
*
R31
ICD-10 Finland
Unspecified haematuria
2.8
8.3
46
186
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
9.4
8.2
16
18
N48.5
ICD-10 Finland
Ulcer of penis
23.0
8.1
11
5
N35.9
ICD-10 Finland
Urethral stricture, unspecified
8.9
8.0
16
19
J01MA12
ATC
levofloxacin; systemic
2.5
7.9
57
263
KF8AE
NOMESCO Finland
Ultrasound examination of scrotum
4.8
7.8
18
40
JN5DR
NOMESCO Finland
PET-CT of upper body metabolism
46.5
7.8
9
*
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
10.5
7.6
14
14
JN2BG
NOMESCO Finland
MRI examination of lower part of abdoment with high intensity magnet
26.0
7.6
10
*
XJH00
NOMESCO Finland
Transanal ultrasonography
3.4
7.6
29
94
WX404
NOMESCO Finland
Intravenous generell anesthesy
2.8
7.5
42
170
M05BX04
ATC
denosumab; parenteral
8.1
7.5
16
21
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
2.4
7.5
62
304
Y83
ICD-10 Finland
Surgical operation and other surgical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
3.7
7.5
25
74
QBB05
NOMESCO Finland
Revision of wound of skin of trunk
14.0
7.5
12
9
ZX090
NOMESCO Finland
Other technic of radiotherapy
82.6
7.5
8
*
WX302
NOMESCO Finland
Thoracal epidural anesthesy
8.8
7.4
15
18
TKC10
NOMESCO Finland
Percutaneous puncture of bladder
8.8
7.4
15
18
8070/3-C44.9
ICD-O-3
Squamous cell carcinoma, NOS, of skin, NOS
+∞
7.3
7
*
8090/3-C44.3
ICD-O-3
Basal cell carcinoma, NOS, of skin of other and unspecified parts of face
+∞
7.3
7
*
Y78
ICPC
Malign neopl male genital other
+∞
7.3
7
*
C83.31
ICD-10 Finland
Diffuse lymphoma with large B cells
+∞
7.3
7
*
WF004
NOMESCO Finland
Palliative radiotherapy
+∞
7.3
7
*
KE3AT
NOMESCO Finland
Transrectal gold marker implantation in prostate under ultrasound guidance
+∞
7.3
7
*
XZZ00
NOMESCO Finland
Active surveillance of a diagnosed cancer
+∞
7.3
7
*
8051/3-C60.9
ICD-O-3
Verrucous carcinoma, NOS, of penis, NOS
+∞
7.3
7
*
KGW96
NOMESCO Finland
Other operation on penis
+∞
7.3
7
*
PJD44
NOMESCO Finland
Excision of iliac lymph nodes
+∞
7.3
7
*
L02AE03
ATC
goserelin; implant
+∞
7.3
7
*
ZXE20
NOMESCO Finland
More than three and less than five hours
2.8
7.3
39
154
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.3
7.3
74
397
QBA10
NOMESCO Finland
Incision of skin of trunk
20.8
7.2
10
5
JN3AD
NOMESCO Finland
Abdominal CT examination
2.8
6.8
36
141
Z3231
NOMESCO Finland
Registered nurse
2.2
6.6
66
349
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
2.9
6.6
32
120
PJ2AE
NOMESCO Finland
Lymphnode ultrasound examination
71.7
6.5
7
*
KC1GB
NOMESCO Finland
Cystography with X-ray
71.7
6.5
7
*
L02AE04
ATC
triptorelin; parenteral
+∞
6.3
6
*
8051/3-C60.1
ICD-O-3
Verrucous carcinoma, NOS, of glans penis
+∞
6.3
6
*
WD415
NOMESCO Finland
Demanding antibody therapy of methastized malignancy
+∞
6.3
6
*
C609, 8086, 3
ICD-O-3
+∞
6.3
6
*
WD205
NOMESCO Finland
Therapy of methastized malignancy with hormones
+∞
6.3
6
*
KGA10
NOMESCO Finland
Incision of prepuce
+∞
6.3
6
*
C64.88
ICD-10 Finland
Other malignant neoplasm of kidney, except renal pelvis
+∞
6.3
6
*
UKC05
NOMESCO Finland
Cystoscopy and bladder biopsy
27.5
6.3
8
*
ZX112
NOMESCO Finland
Subcutaneous
27.5
6.3
8
*
D07BB04
ATC
hydrocortisone butyrate and antiseptics; topical
2.7
6.1
35
143
ZXE00
NOMESCO Finland
One hour or less
2.0
6.0
87
529

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Urology
34 [38004474]
1.5e+00
2.4e+00
4.7e+00
1.0e+50
5.4e+00
4.6e+00
3.3e+00
cases:29.91%
controls:8.46%
cases:27.47%
controls:3.46%
cases:31.76%
controls:0.43%
cases:44.21%
controls:0.00%
cases:50.66%
controls:0.47%
cases:78.20%
controls:3.37%
cases:76.13%
controls:10.76%
70
198
164
2142
64
81
169
2259
74
10
159
2330
103
0
130
2340
116
11
113
2324
165
76
46
2176
118
198
37
1643
Outpatient Visit
OP [9202]
3.4e-01
6.1e-01
1.5e+00
4.8e+00
2.2e+00
2.3e+00
1.1e+00
cases:76.92%
controls:70.38%
cases:66.09%
controls:51.41%
cases:33.05%
controls:9.87%
cases:32.62%
controls:0.38%
cases:48.91%
controls:9.98%
cases:91.47%
controls:51.20%
cases:92.26%
controls:79.74%
180
1647
54
693
154
1203
79
1137
77
231
156
2109
76
9
157
2331
112
233
117
2102
193
1153
18
1099
143
1468
12
373
Blood group antibody screen [Presence] in Serum or Plasma
890-4 [3001079]
2.1e-01
4.6e-01
3.0e+00
1.0e+50
4.5e+00
2.6e+00
7.8e-01
cases:8.97%
controls:7.39%
cases:6.44%
controls:4.15%
cases:7.73%
controls:0.43%
cases:2.15%
controls:0.00%
cases:15.72%
controls:0.21%
cases:28.91%
controls:2.93%
cases:22.58%
controls:11.79%
21
173
213
2167
15
97
218
2243
18
10
215
2330
5
0
228
2340
36
5
193
2330
61
66
150
2186
35
217
120
1624
General Surgery
2 [38004447]
5.8e-01
1.1e+00
2.7e+00
—
3.4e+00
1.9e+00
1.0e+00
cases:25.64%
controls:16.24%
cases:13.30%
controls:5.09%
cases:7.73%
controls:0.56%
—
—
cases:11.79%
controls:0.43%
cases:27.01%
controls:5.02%
cases:30.97%
controls:13.69%
60
380
174
1960
31
119
202
2221
18
13
215
2327
—
27
10
202
2325
57
113
154
2139
48
252
107
1589
Clinical & Laboratory Dermatological Immunology Physician
207NI0002X [38003841]
9.0e-01
1.6e+00
2.6e+00
1.0e+50
2.3e+00
1.6e+00
1.3e+00
cases:11.11%
controls:4.83%
cases:12.02%
controls:2.56%
cases:7.73%
controls:0.64%
cases:5.15%
controls:0.00%
cases:6.11%
controls:0.64%
cases:9.95%
controls:2.26%
cases:17.42%
controls:5.32%
26
113
208
2227
28
60
205
2280
18
15
215
2325
12
0
221
2340
14
15
215
2320
21
51
190
2201
27
98
128
1743
Bacteria [#/volume] in Urine by Automated count
51480-2 [3031040]
4.5e-01
8.2e-01
3.1e+00
—
3.3e+00
2.1e+00
7.8e-01
cases:17.95%
controls:12.22%
cases:13.73%
controls:6.58%
cases:16.31%
controls:0.85%
—
—
cases:19.65%
controls:0.90%
cases:36.02%
controls:6.35%
cases:36.13%
controls:20.64%
42
286
192
2054
32
154
201
2186
38
20
195
2320
—
45
21
184
2314
76
143
135
2109
56
380
99
1461
Casts [#/volume] in Urine by Automated count
51483-6 [3030467]
5.0e-01
2.9e-01
3.3e+00
—
3.0e+00
2.2e+00
8.1e-01
cases:6.84%
controls:4.27%
cases:3.86%
controls:2.91%
cases:9.44%
controls:0.38%
—
—
cases:10.04%
controls:0.56%
cases:18.01%
controls:2.40%
cases:18.06%
controls:8.91%
16
100
218
2240
9
68
224
2272
22
9
211
2331
—
23
13
206
2322
38
54
173
2198
28
164
127
1677
Erythrocytes [#/volume] in Urine
30391-7 [3002582]
4.2e-01
5.4e-01
3.2e+00
—
3.0e+00
2.1e+00
7.6e-01
cases:7.69%
controls:5.21%
cases:5.58%
controls:3.33%
cases:10.30%
controls:0.47%
—
—
cases:11.79%
controls:0.64%
cases:21.33%
controls:3.24%
cases:20.65%
controls:10.86%
18
122
216
2218
13
78
220
2262
24
11
209
2329
—
27
15
202
2320
45
73
166
2179
32
200
123
1641
cefalexin; oral
J01DB01 [21602870]
3.6e-01
7.7e-01
2.9e+00
—
3.3e+00
2.1e+00
5.4e-01
cases:33.76%
controls:26.28%
cases:16.74%
controls:8.50%
cases:12.45%
controls:0.81%
—
—
cases:19.21%
controls:0.86%
cases:40.28%
controls:7.50%
cases:39.35%
controls:27.38%
79
615
155
1725
39
199
194
2141
29
19
204
2321
—
44
20
185
2315
85
169
126
2083
61
504
94
1337
Blood type and Crossmatch panel - Blood
34531-4 [3044640]
7.6e-02
5.3e-01
2.0e+00
1.0e+50
3.6e+00
2.6e+00
7.9e-01
cases:5.56%
controls:5.17%
cases:3.86%
controls:2.31%
cases:2.58%
controls:0.34%
cases:2.15%
controls:0.00%
cases:6.99%
controls:0.21%
cases:22.27%
controls:2.00%
cases:16.77%
controls:8.37%
13
121
221
2219
9
54
224
2286
6
8
227
2332
5
0
228
2340
16
5
213
2330
47
45
164
2207
26
154
129
1687
Epithelial cells [#/volume] in Urine
30383-4 [3000850]
4.2e-01
8.0e-01
3.1e+00
—
2.8e+00
2.0e+00
1.0e+00
cases:5.13%
controls:3.42%
cases:4.29%
controls:1.97%
cases:5.58%
controls:0.26%
—
—
cases:4.80%
controls:0.30%
cases:12.32%
controls:1.91%
cases:14.84%
controls:5.98%
12
80
222
2260
10
46
223
2294
13
6
220
2334
—
11
7
218
2328
26
43
185
2209
23
110
132
1731
Epithelial cells.squamous [#/volume] in Urine by Automated count
51486-9 [3029879]
5.3e-01
—
3.4e+00
—
3.0e+00
2.1e+00
4.6e-01
cases:3.85%
controls:2.31%
—
—
cases:6.01%
controls:0.21%
—
—
cases:7.42%
controls:0.39%
cases:11.85%
controls:1.55%
cases:8.39%
controls:5.49%
9
54
225
2286
—
14
5
219
2335
—
17
9
212
2326
25
35
186
2217
13
101
142
1740
Cystoscopy
UKC02 [2001306005]
1.7e+00
2.2e+00
—
—
—
2.8e+00
1.8e+00
cases:11.97%
controls:2.52%
cases:5.15%
controls:0.60%
—
—
—
—
—
—
cases:8.53%
controls:0.58%
cases:16.13%
controls:2.99%
28
59
206
2281
12
14
221
2326
—
—
—
18
13
193
2239
25
55
130
1786
Bacteria [Presence] in Urine
87829-8 [36304419]
4.8e-01
2.2e-02
3.2e+00
—
3.1e+00
2.1e+00
7.1e-01
cases:6.41%
controls:4.06%
cases:2.58%
controls:2.52%
cases:9.01%
controls:0.38%
—
—
cases:10.04%
controls:0.51%
cases:16.11%
controls:2.40%
cases:15.48%
controls:8.26%
15
95
219
2245
6
59
227
2281
21
9
212
2331
—
23
12
206
2323
34
54
177
2198
24
152
131
1689
Body CT examination
JN4AD [2001310897]
—
2.2e+00
1.0e+50
—
1.0e+50
3.9e+00
2.3e+00
—
—
cases:2.58%
controls:0.30%
cases:2.15%
controls:0.00%
—
—
cases:4.37%
controls:0.00%
cases:11.37%
controls:0.27%
cases:12.26%
controls:1.36%
—
6
7
227
2333
5
0
228
2340
—
10
0
219
2335
24
6
187
2246
19
25
136
1816
Leukocytes [#/volume] in Urine
30405-5 [3018095]
4.6e-01
6.0e-01
3.2e+00
—
3.0e+00
2.0e+00
5.9e-01
cases:8.55%
controls:5.56%
cases:6.44%
controls:3.63%
cases:11.59%
controls:0.51%
—
—
cases:11.35%
controls:0.64%
cases:21.80%
controls:3.77%
cases:20.65%
controls:12.60%
20
130
214
2210
15
85
218
2255
27
12
206
2328
—
26
15
203
2320
46
85
165
2167
32
232
123
1609
Outpatient Hospital
22 [8756]
1.9e-01
2.0e-01
2.3e+00
—
3.0e+00
2.1e+00
7.1e-01
cases:29.06%
controls:25.34%
cases:9.01%
controls:7.48%
cases:9.44%
controls:0.98%
—
—
cases:16.59%
controls:0.94%
cases:33.18%
controls:5.95%
cases:30.97%
controls:18.03%
68
593
166
1747
21
175
212
2165
22
23
211
2317
—
38
22
191
2313
70
134
141
2118
48
332
107
1509
More than one and less than three hours
ZXE10 [2001311401]
5.0e-02
8.8e-01
—
1.0e+50
3.6e+00
3.2e+00
1.3e+00
cases:5.56%
controls:5.30%
cases:3.43%
controls:1.45%
—
—
cases:3.43%
controls:0.00%
cases:6.99%
controls:0.21%
cases:17.54%
controls:0.84%
cases:10.97%
controls:3.15%
13
124
221
2216
8
34
225
2306
—
8
0
225
2340
16
5
213
2330
37
19
174
2233
17
58
138
1783
oxycodone; oral, parenteral
N02AA05 [21604260]
7.4e-01
1.8e+00
—
—
2.8e+00
2.4e+00
1.1e+00
cases:2.56%
controls:1.24%
cases:3.00%
controls:0.51%
—
—
—
—
cases:3.93%
controls:0.26%
cases:7.11%
controls:0.71%
cases:8.39%
controls:2.99%
6
29
228
2311
7
12
226
2328
—
—
9
6
220
2329
15
16
196
2236
13
55
142
1786
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
-2.9e-02
1.6e-01
1.9e+00
3.6e+00
1.8e+00
7.0e-01
2.8e-01
cases:37.18%
controls:37.86%
cases:35.62%
controls:32.05%
cases:28.33%
controls:5.77%
cases:7.30%
controls:0.21%
cases:30.57%
controls:6.68%
cases:50.24%
controls:33.39%
cases:64.52%
controls:57.90%
87
886
147
1454
83
750
150
1590
66
135
167
2205
17
5
216
2335
70
156
159
2179
106
752
105
1500
100
1066
55
775
Urinalysis microscopic panel [#/volume] - Urine by Automated count
50554-5 [3029287]
3.7e-01
3.6e-01
3.1e+00
—
2.6e+00
2.1e+00
6.9e-01
cases:8.97%
controls:6.37%
cases:5.15%
controls:3.63%
cases:10.73%
controls:0.51%
—
—
cases:11.35%
controls:0.90%
cases:21.33%
controls:3.29%
cases:21.29%
controls:11.95%
21
149
213
2191
12
85
221
2255
25
12
208
2328
—
26
21
203
2314
45
74
166
2178
33
220
122
1621
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
-7.8e-02
8.6e-02
1.8e+00
3.4e+00
1.9e+00
7.8e-01
2.7e-01
cases:33.33%
controls:35.09%
cases:30.47%
controls:28.68%
cases:23.18%
controls:4.62%
cases:6.87%
controls:0.26%
cases:27.95%
controls:5.48%
cases:47.87%
controls:29.57%
cases:60.65%
controls:54.10%
78
821
156
1519
71
671
162
1669
54
108
179
2232
16
6
217
2334
64
128
165
2207
101
666
110
1586
94
996
61
845
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
-6.0e-02
6.1e-02
1.8e+00
3.4e+00
1.8e+00
7.6e-01
2.5e-01
cases:34.19%
controls:35.56%
cases:30.47%
controls:29.19%
cases:23.18%
controls:4.66%
cases:6.87%
controls:0.26%
cases:27.95%
controls:5.78%
cases:47.87%
controls:30.11%
cases:60.65%
controls:54.59%
80
832
154
1508
71
683
162
1657
54
109
179
2231
16
6
217
2334
64
135
165
2200
101
678
110
1574
94
1005
61
836
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
4.0e-02
4.1e-01
1.5e+00
3.5e+00
1.7e+00
1.0e+00
4.9e-01
cases:29.06%
controls:28.25%
cases:24.46%
controls:17.65%
cases:12.45%
controls:3.16%
cases:6.44%
controls:0.21%
cases:17.03%
controls:3.47%
cases:40.28%
controls:19.40%
cases:55.48%
controls:43.35%
68
661
166
1679
57
413
176
1927
29
74
204
2266
15
5
218
2335
39
81
190
2254
85
437
126
1815
86
798
69
1043
metoclopramide; oral, parenteral, rectal
A03FA01 [21600484]
1.1e+00
2.6e+00
—
—
—
3.3e+00
1.8e+00
cases:2.99%
controls:0.98%
cases:3.86%
controls:0.30%
—
—
—
—
—
—
cases:10.90%
controls:0.44%
cases:10.32%
controls:1.85%
7
23
227
2317
9
7
224
2333
—
—
—
23
10
188
2242
16
34
139
1807
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
-7.0e-03
-1.3e-02
1.9e+00
3.2e+00
1.9e+00
6.9e-01
1.9e-01
cases:23.93%
controls:24.06%
cases:21.03%
controls:21.24%
cases:22.32%
controls:4.15%
cases:5.15%
controls:0.21%
cases:24.02%
controls:4.63%
cases:36.02%
controls:22.07%
cases:44.52%
controls:39.87%
56
563
178
1777
49
497
184
1843
52
97
181
2243
12
5
221
2335
55
108
174
2227
76
497
135
1755
69
734
86
1107
MCH [Entitic mass]
28539-5 [3035941]
-5.4e-03
8.6e-02
1.8e+00
3.1e+00
1.8e+00
5.7e-01
1.8e-01
cases:39.32%
controls:39.44%
cases:35.62%
controls:33.68%
cases:29.61%
controls:6.54%
cases:6.87%
controls:0.34%
cases:31.00%
controls:7.19%
cases:48.82%
controls:34.95%
cases:63.87%
controls:59.70%
92
923
142
1417
83
788
150
1552
69
153
164
2187
16
8
217
2332
71
168
158
2167
103
787
108
1465
99
1099
56
742
Platelets [#/volume] in Blood
26515-7 [3007461]
0.0e+00
1.1e-01
1.8e+00
3.1e+00
1.8e+00
5.7e-01
1.8e-01
cases:39.32%
controls:39.32%
cases:36.05%
controls:33.63%
cases:29.61%
controls:6.54%
cases:6.87%
controls:0.34%
cases:31.00%
controls:7.19%
cases:48.82%
controls:34.95%
cases:63.87%
controls:59.59%
92
920
142
1420
84
787
149
1553
69
153
164
2187
16
8
217
2332
71
168
158
2167
103
787
108
1465
99
1097
56
744
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
-5.4e-03
1.0e-01
1.8e+00
3.1e+00
1.8e+00
5.7e-01
1.8e-01
cases:39.32%
controls:39.44%
cases:36.05%
controls:33.72%
cases:29.61%
controls:6.54%
cases:6.87%
controls:0.34%
cases:31.00%
controls:7.19%
cases:48.82%
controls:34.99%
cases:63.87%
controls:59.70%
92
923
142
1417
84
789
149
1551
69
153
164
2187
16
8
217
2332
71
168
158
2167
103
788
108
1464
99
1099
56
742
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
-5.4e-03
1.0e-01
1.8e+00
3.1e+00
1.8e+00
5.7e-01
1.7e-01
cases:39.32%
controls:39.44%
cases:36.05%
controls:33.72%
cases:29.61%
controls:6.54%
cases:6.87%
controls:0.34%
cases:31.00%
controls:7.19%
cases:48.82%
controls:35.04%
cases:63.87%
controls:59.75%
92
923
142
1417
84
789
149
1551
69
153
164
2187
16
8
217
2332
71
168
158
2167
103
789
108
1463
99
1100
56
741
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
-8.9e-03
9.9e-02
1.8e+00
3.1e+00
1.8e+00
5.7e-01
1.7e-01
cases:39.32%
controls:39.53%
cases:36.05%
controls:33.80%
cases:29.61%
controls:6.58%
cases:6.87%
controls:0.34%
cases:31.00%
controls:7.19%
cases:48.82%
controls:35.04%
cases:63.87%
controls:59.80%
92
925
142
1415
84
791
149
1549
69
154
164
2186
16
8
217
2332
71
168
158
2167
103
789
108
1463
99
1101
56
740
Leukocytes [#/volume] in Blood
26464-8 [3010813]
-1.1e-02
1.1e-01
1.8e+00
3.1e+00
1.8e+00
5.7e-01
1.7e-01
cases:39.32%
controls:39.57%
cases:36.05%
controls:33.63%
cases:29.61%
controls:6.58%
cases:6.87%
controls:0.34%
cases:31.00%
controls:7.19%
cases:48.82%
controls:35.04%
cases:63.87%
controls:59.80%
92
926
142
1414
84
787
149
1553
69
154
164
2186
16
8
217
2332
71
168
158
2167
103
789
108
1463
99
1101
56
740
Ultrasound measurement of residual urine
KC1EE [2001305918]
1.1e+00
1.7e+00
—
—
—
2.5e+00
1.8e+00
cases:8.12%
controls:2.78%
cases:4.72%
controls:0.90%
—
—
—
—
—
—
cases:10.43%
controls:0.93%
cases:18.06%
controls:3.42%
19
65
215
2275
11
21
222
2319
—
—
—
22
21
189
2231
28
63
127
1778
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
-5.4e-03
1.1e-01
1.8e+00
3.1e+00
1.8e+00
5.7e-01
1.8e-01
cases:39.32%
controls:39.44%
cases:36.05%
controls:33.63%
cases:29.18%
controls:6.58%
cases:6.87%
controls:0.34%
cases:31.00%
controls:7.19%
cases:48.82%
controls:34.99%
cases:63.87%
controls:59.70%
92
923
142
1417
84
787
149
1553
68
154
165
2186
16
8
217
2332
71
168
158
2167
103
788
108
1464
99
1099
56
742
Uroflowmetry
44856007 [4261340]
1.1e+00
1.9e+00
—
—
—
2.5e+00
1.6e+00
cases:10.68%
controls:3.85%
cases:6.87%
controls:1.07%
—
—
—
—
—
—
cases:9.95%
controls:0.89%
cases:15.48%
controls:3.59%
25
90
209
2250
16
25
217
2315
—
—
—
21
20
190
2232
24
66
131
1775
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
3.7e-01
5.7e-01
2.0e+00
—
2.5e+00
1.7e+00
8.5e-01
cases:11.97%
controls:8.59%
cases:8.15%
controls:4.79%
cases:5.15%
controls:0.73%
—
—
cases:6.11%
controls:0.51%
cases:20.85%
controls:4.62%
cases:29.68%
controls:15.32%
28
201
206
2139
19
112
214
2228
12
17
221
2323
—
14
12
215
2323
44
104
167
2148
46
282
109
1559
Immunohistochemistry procedure
117617002 [4035726]
2.1e+00
2.3e+00
—
1.0e+50
—
4.1e+00
3.0e+00
cases:2.14%
controls:0.26%
cases:2.15%
controls:0.21%
—
—
cases:6.87%
controls:0.00%
—
—
cases:13.74%
controls:0.27%
cases:5.16%
controls:0.27%
5
6
229
2334
5
5
228
2335
—
16
0
217
2340
—
29
6
182
2246
8
5
147
1836
Glucose [Moles/volume] in Serum or Plasma
14749-6 [3013826]
-8.6e-02
1.8e-01
2.1e+00
1.0e+50
2.6e+00
1.7e+00
6.3e-01
cases:11.97%
controls:12.91%
cases:8.15%
controls:6.92%
cases:5.58%
controls:0.68%
cases:3.43%
controls:0.00%
cases:8.30%
controls:0.69%
cases:28.44%
controls:6.75%
cases:32.26%
controls:20.15%
28
302
206
2038
19
162
214
2178
13
16
220
2324
8
0
225
2340
19
16
210
2319
60
152
151
2100
50
371
105
1470
dexamethasone; oral, parenteral
H02AB02 [21602730]
1.0e+00
2.0e+00
—
—
—
2.9e+00
2.1e+00
cases:2.56%
controls:0.94%
cases:2.58%
controls:0.34%
—
—
—
—
—
—
cases:6.16%
controls:0.36%
cases:9.68%
controls:1.30%
6
22
228
2318
6
8
227
2332
—
—
—
13
8
198
2244
15
24
140
1817
Laboratory Visit
OMOP4822461 [32036]
-1.7e-02
1.1e-01
1.5e+00
3.9e+00
1.6e+00
4.7e-01
1.2e-01
cases:42.74%
controls:43.16%
cases:42.92%
controls:40.17%
cases:40.34%
controls:12.65%
cases:27.90%
controls:0.81%
cases:41.48%
controls:12.33%
cases:54.03%
controls:42.23%
cases:66.45%
controls:63.82%
100
1010
134
1330
100
940
133
1400
94
296
139
2044
65
19
168
2321
95
288
134
2047
114
951
97
1301
103
1175
52
666
Prothrombin time (PT) actual/Normal
5894-1 [3033658]
5.4e-02
-5.5e-02
2.2e+00
—
3.0e+00
1.8e+00
7.4e-01
cases:5.13%
controls:4.87%
cases:2.15%
controls:2.26%
cases:4.72%
controls:0.56%
—
—
cases:9.17%
controls:0.51%
cases:12.80%
controls:2.26%
cases:12.26%
controls:6.25%
12
114
222
2226
5
53
228
2287
11
13
222
2327
—
21
12
208
2323
27
51
184
2201
19
115
136
1726
Inpatient Hospital
21 [8717]
2.3e-01
2.9e-01
2.1e+00
—
2.3e+00
1.7e+00
8.1e-01
cases:37.61%
controls:32.48%
cases:14.16%
controls:10.98%
cases:12.45%
controls:1.67%
—
—
cases:17.03%
controls:1.93%
cases:38.86%
controls:10.70%
cases:43.87%
controls:25.86%
88
760
146
1580
33
257
200
2083
29
39
204
2301
—
39
45
190
2290
82
241
129
2011
68
476
87
1365
Osmolality of Urine
2695-5 [3026782]
2.4e-01
7.0e-01
2.6e+00
—
2.2e+00
1.9e+00
6.0e-01
cases:4.70%
controls:3.72%
cases:4.29%
controls:2.18%
cases:4.29%
controls:0.34%
—
—
cases:3.93%
controls:0.47%
cases:10.43%
controls:1.78%
cases:9.68%
controls:5.54%
11
87
223
2253
10
51
223
2289
10
8
223
2332
—
9
11
220
2324
22
40
189
2212
15
102
140
1739
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
1.4e-01
3.0e-01
2.1e+00
—
1.8e+00
1.5e+00
1.0e+00
cases:8.97%
controls:7.86%
cases:6.87%
controls:5.17%
cases:5.15%
controls:0.64%
—
—
cases:4.37%
controls:0.77%
cases:19.43%
controls:4.93%
cases:27.74%
controls:11.95%
21
184
213
2156
16
121
217
2219
12
15
221
2325
—
10
18
219
2317
41
111
170
2141
43
220
112
1621
Intravenous
ZX120 [2001311495]
1.0e+00
1.9e+00
—
—
—
2.6e+00
1.8e+00
cases:2.56%
controls:0.94%
cases:3.00%
controls:0.47%
—
—
—
—
—
—
cases:3.32%
controls:0.27%
cases:5.81%
controls:0.98%
6
22
228
2318
7
11
226
2329
—
—
—
7
6
204
2246
9
18
146
1823
Case Management Agency
251B00000X [38004193]
-1.3e-02
7.8e-02
9.1e-01
3.5e+00
1.1e+00
6.9e-01
2.4e-03
cases:65.38%
controls:65.68%
cases:62.23%
controls:60.38%
cases:42.92%
controls:23.29%
cases:30.47%
controls:1.28%
cases:48.03%
controls:23.90%
cases:76.78%
controls:62.48%
cases:80.65%
controls:80.61%
153
1537
81
803
145
1413
88
927
100
545
133
1795
71
30
162
2310
110
558
119
1777
162
1407
49
845
125
1484
30
357
tinzaparin; parenteral
B01AB10 [21600981]
—
2.3e+00
—
—
—
3.8e+00
—
—
—
cases:2.58%
controls:0.26%
—
—
—
—
—
—
cases:9.00%
controls:0.22%
—
—
—
6
6
227
2334
—
—
—
19
5
192
2247
—
Tissue Pathology biopsy report
66121-5 [40768804]
5.7e-01
1.4e+00
—
1.0e+50
—
3.2e+00
1.4e+00
cases:8.55%
controls:5.04%
cases:6.87%
controls:1.75%
—
—
cases:10.30%
controls:0.00%
—
—
cases:25.12%
controls:1.38%
cases:19.35%
controls:5.43%
20
118
214
2222
16
41
217
2299
—
24
0
209
2340
—
53
31
158
2221
30
100
125
1741
Extensive body CT
JN4BD [2001310899]
—
2.8e+00
—
1.0e+50
—
—
3.1e+00
—
—
cases:3.43%
controls:0.21%
—
—
cases:3.00%
controls:0.00%
—
—
—
—
cases:9.68%
controls:0.49%
—
8
5
225
2335
—
7
0
226
2340
—
—
15
9
140
1832
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
2.1e-01
4.0e-01
1.7e+00
1.0e+50
1.8e+00
1.4e+00
8.6e-01
cases:20.09%
controls:16.97%
cases:14.16%
controls:10.00%
cases:8.15%
controls:1.54%
cases:2.15%
controls:0.00%
cases:8.30%
controls:1.46%
cases:30.81%
controls:10.26%
cases:47.74%
controls:27.92%
47
397
187
1943
33
234
200
2106
19
36
214
2304
5
0
228
2340
19
34
210
2301
65
231
146
2021
74
514
81
1327
ciprofloxacin; oral, parenteral
J01MA02 [21603009]
7.4e-01
9.3e-01
2.6e+00
—
—
1.4e+00
9.4e-01
cases:11.97%
controls:6.07%
cases:6.44%
controls:2.65%
cases:3.43%
controls:0.26%
—
—
—
—
cases:9.48%
controls:2.40%
cases:15.48%
controls:6.68%
28
142
206
2198
15
62
218
2278
8
6
225
2334
—
—
20
54
191
2198
24
123
131
1718
12 lead EKG panel
34534-8 [3044889]
-4.4e-02
-4.2e-01
2.3e+00
—
2.2e+00
1.2e+00
1.2e-01
cases:18.80%
controls:19.49%
cases:7.73%
controls:11.28%
cases:10.30%
controls:1.11%
—
—
cases:10.92%
controls:1.28%
cases:27.49%
controls:10.35%
cases:31.61%
controls:29.01%
44
456
190
1884
18
264
215
2076
24
26
209
2314
—
25
30
204
2305
58
233
153
2019
49
534
106
1307
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
-1.4e-01
-1.3e-01
1.6e+00
2.6e+00
1.5e+00
2.8e-01
-5.1e-02
cases:26.92%
controls:29.74%
cases:21.46%
controls:23.68%
cases:21.89%
controls:5.30%
cases:3.43%
controls:0.26%
cases:20.52%
controls:5.44%
cases:29.86%
controls:24.38%
cases:42.58%
controls:43.83%
63
696
171
1644
50
554
183
1786
51
124
182
2216
8
6
225
2334
47
127
182
2208
63
549
148
1703
66
807
89
1034
Urinalysis macro (dipstick) panel - Urine
24357-6 [3037467]
2.7e-01
6.2e-01
2.8e+00
—
1.8e+00
1.1e+00
4.8e-01
cases:17.95%
controls:14.27%
cases:12.88%
controls:7.35%
cases:12.02%
controls:0.85%
—
—
cases:6.11%
controls:1.11%
cases:18.96%
controls:7.42%
cases:32.90%
controls:23.25%
42
334
192
2006
30
172
203
2168
28
20
205
2320
—
14
26
215
2309
40
167
171
2085
51
428
104
1413
Bacteria identified in Urine by Culture
630-4 [3026008]
7.3e-01
8.9e-01
—
—
3.3e+00
2.2e+00
7.3e-01
cases:6.41%
controls:3.21%
cases:5.15%
controls:2.18%
—
—
—
—
cases:8.30%
controls:0.34%
cases:15.64%
controls:2.09%
cases:14.84%
controls:7.71%
15
75
219
2265
12
51
221
2289
—
—
19
8
210
2327
33
47
178
2205
23
142
132
1699
Scheduled procedure
ZXD10 [2001311387]
2.0e-01
9.4e-01
2.7e+00
1.0e+50
—
2.7e+00
8.0e-01
cases:7.69%
controls:6.37%
cases:3.43%
controls:1.37%
cases:3.00%
controls:0.21%
cases:2.58%
controls:0.00%
—
—
cases:12.32%
controls:0.93%
cases:7.74%
controls:3.64%
18
149
216
2191
8
32
225
2308
7
5
226
2335
6
0
227
2340
—
26
21
185
2231
12
67
143
1774
Normoblasts [#/volume] in Blood
715-3 [3021589]
2.7e-01
6.1e-01
2.0e+00
—
2.3e+00
1.1e+00
2.5e-01
cases:9.83%
controls:7.65%
cases:12.02%
controls:6.92%
cases:6.87%
controls:1.03%
—
—
cases:8.73%
controls:0.94%
cases:19.43%
controls:7.73%
cases:18.71%
controls:15.15%
23
179
211
2161
28
162
205
2178
16
24
217
2316
—
20
22
209
2313
41
174
170
2078
29
279
126
1562
Epithelial cells.non-squamous [#/volume] in Urine by Automated count
51485-1 [3030306]
2.5e-01
—
—
—
3.1e+00
2.2e+00
5.0e-01
cases:2.56%
controls:2.01%
—
—
—
—
—
—
cases:7.42%
controls:0.34%
cases:11.37%
controls:1.47%
cases:9.68%
controls:6.08%
6
47
228
2293
—
—
—
17
8
212
2327
24
33
187
2219
15
112
140
1729
Treatment plan or consultation
WZC00 [2001310885]
6.9e-01
1.6e+00
—
—
—
2.4e+00
1.1e+00
cases:6.41%
controls:3.33%
cases:6.44%
controls:1.37%
—
—
—
—
—
—
cases:14.22%
controls:1.55%
cases:14.19%
controls:5.11%
15
78
219
2262
15
32
218
2308
—
—
—
30
35
181
2217
22
94
133
1747
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
1.2e-01
3.0e-01
2.0e+00
—
2.1e+00
9.7e-01
4.6e-01
cases:26.50%
controls:24.23%
cases:27.47%
controls:21.92%
cases:21.89%
controls:3.72%
—
—
cases:25.33%
controls:4.03%
cases:44.08%
controls:23.09%
cases:54.84%
controls:43.35%
62
567
172
1773
64
513
169
1827
51
87
182
2253
—
58
94
171
2241
93
520
118
1732
85
798
70
1043
Balanoposthitis
N48.1 [45567850]
2.3e+00
—
1.0e+50
—
1.0e+50
2.7e+00
1.5e+00
cases:4.27%
controls:0.43%
—
—
cases:5.58%
controls:0.00%
—
—
cases:2.62%
controls:0.00%
cases:3.79%
controls:0.27%
cases:3.23%
controls:0.71%
10
10
224
2330
—
13
0
220
2340
—
6
0
223
2335
8
6
203
2246
5
13
150
1828
Extensive abdominal CT
JN3BD [2001305556]
7.9e-01
—
—
—
—
2.6e+00
2.3e+00
cases:2.14%
controls:0.98%
—
—
—
—
—
—
—
—
cases:4.74%
controls:0.36%
cases:6.45%
controls:0.65%
5
23
229
2317
—
—
—
—
10
8
201
2244
10
12
145
1829
Calcium [Moles/volume] in Serum or Plasma
2000-8 [3015377]
3.5e-01
6.7e-01
—
—
2.3e+00
1.5e+00
1.0e+00
cases:5.98%
controls:4.27%
cases:4.72%
controls:2.48%
—
—
—
—
cases:2.62%
controls:0.26%
cases:9.95%
controls:2.35%
cases:16.77%
controls:6.84%
14
100
220
2240
11
58
222
2282
—
—
6
6
223
2329
21
53
190
2199
26
126
129
1715
General anaesthesia
WX402 [2001310806]
—
—
—
1.0e+50
1.0e+50
3.5e+00
1.4e+00
—
—
—
—
—
—
cases:3.43%
controls:0.00%
cases:5.68%
controls:0.00%
cases:19.91%
controls:0.75%
cases:12.90%
controls:3.59%
—
—
—
8
0
225
2340
13
0
216
2335
42
17
169
2235
20
66
135
1775
tramadol; oral, parenteral, rectal
N02AX02 [21604298]
9.5e-02
4.6e-01
1.1e+00
—
2.1e+00
1.8e+00
8.6e-01
cases:8.12%
controls:7.44%
cases:4.72%
controls:3.03%
cases:2.15%
controls:0.73%
—
—
cases:4.80%
controls:0.60%
cases:14.22%
controls:2.66%
cases:16.13%
controls:7.50%
19
174
215
2166
11
71
222
2269
5
17
228
2323
—
11
14
218
2321
30
60
181
2192
25
138
130
1703
Emergency Room Visit
ER [9203]
1.8e-01
1.9e-01
2.4e+00
1.0e+50
1.4e+00
9.7e-01
5.6e-01
cases:38.89%
controls:34.66%
cases:14.16%
controls:12.05%
cases:10.73%
controls:1.11%
cases:8.15%
controls:0.00%
cases:6.11%
controls:1.54%
cases:27.01%
controls:12.30%
cases:44.52%
controls:31.34%
91
811
143
1529
33
282
200
2058
25
26
208
2314
19
0
214
2340
14
36
215
2299
57
277
154
1975
69
577
86
1264
Thorax X-ray examination
GD1AA [2001303617]
4.4e-01
3.9e-01
—
1.0e+50
2.7e+00
1.1e+00
9.0e-01
cases:13.68%
controls:9.23%
cases:6.87%
controls:4.74%
—
—
cases:3.00%
controls:0.00%
cases:3.06%
controls:0.21%
cases:10.43%
controls:3.77%
cases:23.23%
controls:10.97%
32
216
202
2124
16
111
217
2229
—
7
0
226
2340
7
5
222
2330
22
85
189
2167
36
202
119
1639
Supplier / Service Provider
OMOP5117446 [33004]
-7.5e-01
-1.4e+00
—
—
—
3.9e+00
2.8e+00
cases:11.97%
controls:22.31%
cases:2.15%
controls:8.55%
—
—
—
—
—
—
cases:15.64%
controls:0.36%
cases:14.19%
controls:1.03%
28
522
206
1818
5
200
228
2140
—
—
—
33
8
178
2244
22
19
133
1822
General anesthesia, balanced
WX408 [2001310808]
8.1e-01
1.1e+00
—
1.0e+50
—
2.7e+00
1.6e+00
cases:6.41%
controls:2.95%
cases:3.00%
controls:0.98%
—
—
cases:3.43%
controls:0.00%
—
—
cases:10.90%
controls:0.80%
cases:9.03%
controls:2.01%
15
69
219
2271
7
23
226
2317
—
8
0
225
2340
—
23
18
188
2234
14
37
141
1804
CBC panel - Blood by Automated count
58410-2 [40761511]
2.1e-02
-1.9e-02
1.7e+00
—
1.8e+00
7.1e-01
1.4e-01
cases:33.33%
controls:32.86%
cases:22.75%
controls:23.08%
cases:17.60%
controls:3.89%
—
—
cases:19.65%
controls:4.07%
cases:38.39%
controls:23.53%
cases:50.32%
controls:46.93%
78
769
156
1571
53
540
180
1800
41
91
192
2249
—
45
95
184
2240
81
530
130
1722
78
864
77
977
Skin Pathology biopsy report
65754-4 [40768443]
1.6e+00
2.1e+00
—
1.0e+50
—
—
2.0e+00
cases:2.56%
controls:0.51%
cases:3.00%
controls:0.38%
—
—
cases:2.15%
controls:0.00%
—
—
—
—
cases:4.52%
controls:0.65%
6
12
228
2328
7
9
226
2331
—
5
0
228
2340
—
—
7
12
148
1829
Plastic And Reconstructive Surgery
24 [38004467]
4.7e-01
—
—
—
1.9e+00
2.6e+00
1.5e+00
cases:2.56%
controls:1.62%
—
—
—
—
—
—
cases:2.18%
controls:0.34%
cases:8.06%
controls:0.67%
cases:6.45%
controls:1.58%
6
38
228
2302
—
—
—
5
8
224
2327
17
15
194
2237
10
29
145
1812
Abdominal ultrasound examination
JN3AE [2001305555]
—
—
—
—
—
2.2e+00
1.8e+00
—
—
—
—
—
—
—
—
—
—
cases:3.79%
controls:0.44%
cases:9.03%
controls:1.63%
—
—
—
—
—
8
10
203
2242
14
30
141
1811
pH of Urine
2756-5 [3015736]
4.7e-01
6.2e-01
2.9e+00
—
1.4e+00
9.9e-01
1.1e-01
cases:10.26%
controls:6.67%
cases:6.01%
controls:3.33%
cases:6.01%
controls:0.34%
—
—
cases:2.62%
controls:0.69%
cases:9.00%
controls:3.55%
cases:15.48%
controls:14.12%
24
156
210
2184
14
78
219
2262
14
8
219
2332
—
6
16
223
2319
19
80
192
2172
24
260
131
1581
ibuprofen; oral, parenteral, rectal
M01AE01 [21603967]
4.0e-01
6.5e-01
1.1e+00
—
1.9e+00
1.3e+00
4.3e-01
cases:36.32%
controls:27.61%
cases:19.31%
controls:11.07%
cases:4.72%
controls:1.62%
—
—
cases:10.48%
controls:1.71%
cases:30.33%
controls:10.21%
cases:34.19%
controls:25.31%
85
646
149
1694
45
259
188
2081
11
38
222
2302
—
24
40
205
2295
64
230
147
2022
53
466
102
1375
ibuprofen
R02AX02 [1588667]
4.0e-01
6.5e-01
1.1e+00
—
1.9e+00
1.3e+00
4.3e-01
cases:36.32%
controls:27.61%
cases:19.31%
controls:11.07%
cases:4.72%
controls:1.62%
—
—
cases:10.48%
controls:1.71%
cases:30.33%
controls:10.21%
cases:34.19%
controls:25.31%
85
646
149
1694
45
259
188
2081
11
38
222
2302
—
24
40
205
2295
64
230
147
2022
53
466
102
1375
Nitrite [Presence] in Urine by Test strip
5802-4 [3021601]
3.9e-01
6.0e-01
3.0e+00
—
1.2e+00
9.2e-01
2.6e-01
cases:11.11%
controls:7.82%
cases:8.15%
controls:4.66%
cases:7.73%
controls:0.43%
—
—
cases:3.06%
controls:0.90%
cases:12.32%
controls:5.33%
cases:21.94%
controls:17.82%
26
183
208
2157
19
109
214
2231
18
10
215
2330
—
7
21
222
2314
26
120
185
2132
34
328
121
1513
Teaching
WZC30 [2001310891]
—
1.5e+00
—
—
—
2.7e+00
1.2e+00
—
—
cases:2.58%
controls:0.60%
—
—
—
—
—
—
cases:8.06%
controls:0.58%
cases:8.39%
controls:2.77%
—
6
14
227
2326
—
—
—
17
13
194
2239
13
51
142
1790
Upper gastrointestinal surgery
106 [44777669]
4.1e-01
7.1e-02
2.5e+00
1.0e+50
1.5e+00
1.4e+00
7.1e-01
cases:12.39%
controls:8.55%
cases:3.43%
controls:3.21%
cases:4.29%
controls:0.38%
cases:3.00%
controls:0.00%
cases:2.18%
controls:0.51%
cases:10.43%
controls:2.80%
cases:19.35%
controls:10.54%
29
200
205
2140
8
75
225
2265
10
9
223
2331
7
0
226
2340
5
12
224
2323
22
63
189
2189
30
194
125
1647
Carcinoembryonic Ag [Mass/volume] in Serum or Plasma
2039-6 [3003785]
1.7e+00
—
—
—
—
2.3e+00
1.5e+00
cases:2.56%
controls:0.47%
—
—
—
—
—
—
—
—
cases:3.32%
controls:0.36%
cases:6.45%
controls:1.52%
6
11
228
2329
—
—
—
—
7
8
204
2244
10
28
145
1813
Ketones [Presence] in Urine by Test strip
2514-8 [3035350]
4.0e-01
5.8e-01
2.9e+00
—
1.4e+00
8.7e-01
2.2e-01
cases:11.54%
controls:8.08%
cases:8.15%
controls:4.74%
cases:7.73%
controls:0.47%
—
—
cases:3.49%
controls:0.90%
cases:12.32%
controls:5.55%
cases:21.94%
controls:18.41%
27
189
207
2151
19
111
214
2229
18
11
215
2329
—
8
21
221
2314
26
125
185
2127
34
339
121
1502
Glucose [Presence] in Urine by Test strip
25428-4 [3009261]
3.6e-01
6.9e-01
2.9e+00
—
1.5e+00
8.6e-01
2.6e-01
cases:11.54%
controls:8.33%
cases:9.01%
controls:4.74%
cases:7.73%
controls:0.47%
—
—
cases:3.93%
controls:0.94%
cases:12.32%
controls:5.60%
cases:22.58%
controls:18.41%
27
195
207
2145
21
111
212
2229
18
11
215
2329
—
9
22
220
2313
26
126
185
2126
35
339
120
1502
Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture
13317-3 [3019902]
6.4e-01
—
—
—
1.0e+50
2.3e+00
1.4e+00
cases:3.42%
controls:1.84%
—
—
—
—
—
—
cases:2.18%
controls:0.00%
cases:9.00%
controls:0.98%
cases:9.68%
controls:2.66%
8
43
226
2297
—
—
—
5
0
224
2335
19
22
192
2230
15
49
140
1792
Inpatient Visit
IP [9201]
3.0e-01
4.5e-01
—
1.0e+50
—
2.7e+00
9.6e-01
cases:6.41%
controls:4.83%
cases:4.72%
controls:3.08%
—
—
cases:6.01%
controls:0.00%
—
—
cases:26.07%
controls:2.35%
cases:21.94%
controls:9.72%
15
113
219
2227
11
72
222
2268
—
14
0
219
2340
—
55
53
156
2199
34
179
121
1662
Pathology report gross observation
24419-4 [3002256]
1.0e+00
—
—
1.0e+50
1.0e+50
3.5e+00
9.6e-01
cases:2.99%
controls:1.07%
—
—
—
—
cases:5.58%
controls:0.00%
cases:4.80%
controls:0.00%
cases:11.85%
controls:0.40%
cases:3.87%
controls:1.52%
7
25
227
2315
—
—
13
0
220
2340
11
0
218
2335
25
9
186
2243
6
28
149
1813
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
1.3e-01
6.6e-01
1.4e+00
—
1.3e+00
1.3e+00
8.5e-01
cases:11.11%
controls:9.91%
cases:12.45%
controls:6.84%
cases:6.44%
controls:1.75%
—
—
cases:4.37%
controls:1.28%
cases:21.33%
controls:6.97%
cases:30.32%
controls:15.64%
26
232
208
2108
29
160
204
2180
15
41
218
2299
—
10
30
219
2305
45
157
166
2095
47
288
108
1553
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]
3.9e-02
2.7e-01
1.1e+00
—
2.4e+00
1.1e+00
6.0e-01
cases:8.55%
controls:8.25%
cases:6.87%
controls:5.34%
cases:2.15%
controls:0.73%
—
—
cases:3.93%
controls:0.39%
cases:12.32%
controls:4.40%
cases:21.94%
controls:13.31%
20
193
214
2147
16
125
217
2215
5
17
228
2323
—
9
9
220
2326
26
99
185
2153
34
245
121
1596
Bacteria identified in Skin by Aerobe culture
620-5 [3007853]
9.5e-01
1.2e+00
—
—
—
2.4e+00
1.0e+00
cases:4.70%
controls:1.88%
cases:2.58%
controls:0.81%
—
—
—
—
—
—
cases:9.00%
controls:0.89%
cases:9.68%
controls:3.69%
11
44
223
2296
6
19
227
2321
—
—
—
19
20
192
2232
15
68
140
1773
Short blood count panel - Blood
55429-5 [40758558]
-2.1e-02
6.8e-01
2.2e+00
—
—
1.1e+00
2.1e-01
cases:4.27%
controls:4.36%
cases:4.29%
controls:2.22%
cases:5.15%
controls:0.60%
—
—
—
—
cases:7.11%
controls:2.49%
cases:9.03%
controls:7.44%
10
102
224
2238
10
52
223
2288
12
14
221
2326
—
—
15
56
196
2196
14
137
141
1704
Lymphocytes/Leukocytes in Blood
26478-8 [3002030]
1.0e-01
4.7e-01
1.5e+00
—
1.1e+00
9.8e-01
7.5e-01
cases:9.83%
controls:8.97%
cases:9.44%
controls:6.11%
cases:5.15%
controls:1.24%
—
—
cases:2.62%
controls:0.90%
cases:13.74%
controls:5.64%
cases:24.52%
controls:13.25%
23
210
211
2130
22
143
211
2197
12
29
221
2311
—
6
21
223
2314
29
127
182
2125
38
244
117
1597
Basophils/Leukocytes in Blood
30180-4 [3022096]
1.6e-01
5.0e-01
1.4e+00
—
1.1e+00
9.8e-01
7.9e-01
cases:9.83%
controls:8.50%
cases:9.44%
controls:5.94%
cases:5.15%
controls:1.28%
—
—
cases:2.62%
controls:0.90%
cases:13.74%
controls:5.64%
cases:24.52%
controls:12.87%
23
199
211
2141
22
139
211
2201
12
30
221
2310
—
6
21
223
2314
29
127
182
2125
38
237
117
1604
Intravenous general anesthesia
WX404 [2001310807]
—
—
—
—
—
3.2e+00
7.7e-01
—
—
—
—
—
—
—
—
—
—
cases:7.11%
controls:0.31%
cases:3.23%
controls:1.52%
—
—
—
—
—
15
7
196
2245
5
28
150
1813
Eosinophils/Leukocytes in Blood
26450-7 [3006504]
1.5e-01
4.9e-01
1.4e+00
—
1.1e+00
9.8e-01
7.8e-01
cases:9.83%
controls:8.59%
cases:9.44%
controls:5.98%
cases:5.15%
controls:1.28%
—
—
cases:2.62%
controls:0.90%
cases:13.74%
controls:5.64%
cases:24.52%
controls:12.93%
23
201
211
2139
22
140
211
2200
12
30
221
2310
—
6
21
223
2314
29
127
182
2125
38
238
117
1603
Monocytes/Leukocytes in Blood
26485-3 [3019069]
1.4e-01
4.9e-01
1.4e+00
—
1.1e+00
9.7e-01
7.8e-01
cases:9.83%
controls:8.63%
cases:9.44%
controls:6.03%
cases:5.15%
controls:1.28%
—
—
cases:2.62%
controls:0.90%
cases:13.74%
controls:5.68%
cases:24.52%
controls:12.98%
23
202
211
2138
22
141
211
2199
12
30
221
2310
—
6
21
223
2314
29
128
182
2124
38
239
117
1602
paracetamol; oral, parenteral, rectal
N02BE01 [21604344]
2.4e-01
3.2e-01
7.0e-01
—
1.9e+00
1.2e+00
4.0e-01
cases:38.89%
controls:33.38%
cases:25.75%
controls:20.04%
cases:7.73%
controls:3.97%
—
—
cases:19.65%
controls:3.51%
cases:44.55%
controls:19.27%
cases:52.26%
controls:42.26%
91
781
143
1559
60
469
173
1871
18
93
215
2247
—
45
82
184
2253
94
434
117
1818
81
778
74
1063
Treatment of reopened or infected surgical wound
SPAT1144 [2001700245]
-1.0e+50
-1.0e+50
—
—
—
3.0e+00
—
cases:0.00%
controls:0.73%
cases:0.00%
controls:0.26%
—
—
—
—
—
—
cases:4.27%
controls:0.22%
—
—
0
17
234
2323
0
6
233
2334
—
—
—
9
5
202
2247
—
Leukocyte esterase [Presence] in Urine by Automated test strip
60026-2 [40763086]
3.9e-01
5.6e-01
3.0e+00
—
1.5e+00
8.3e-01
4.4e-01
cases:9.83%
controls:6.88%
cases:6.87%
controls:4.06%
cases:5.58%
controls:0.30%
—
—
cases:3.49%
controls:0.77%
cases:9.48%
controls:4.35%
cases:19.35%
controls:13.42%
23
161
211
2179
16
95
217
2245
13
7
220
2333
—
8
18
221
2317
20
98
191
2154
30
247
125
1594
enoxaparin; parenteral
B01AB05 [21600976]
4.6e-01
6.3e-01
—
—
—
3.0e+00
4.4e-01
cases:6.84%
controls:4.44%
cases:3.00%
controls:1.62%
—
—
—
—
—
—
cases:12.32%
controls:0.71%
cases:6.45%
controls:4.24%
16
104
218
2236
7
38
226
2302
—
—
—
26
16
185
2236
10
78
145
1763
Bicarbonate [Moles/volume] standard in Arterial blood
19230-2 [3014218]
—
—
—
—
—
3.0e+00
—
—
—
—
—
—
—
—
—
—
—
cases:5.69%
controls:0.31%
—
—
—
—
—
—
—
12
7
199
2245
—
Surgical operation and other surgical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
Y83 [45552036]
—
—
—
—
—
2.9e+00
—
—
—
—
—
—
—
—
—
—
—
cases:4.74%
controls:0.27%
—
—
—
—
—
—
—
10
6
201
2246
—
Neutrophils/Leukocytes in Blood
26511-6 [3018010]
4.3e-02
4.6e-01
1.3e+00
—
1.2e+00
9.0e-01
6.8e-01
cases:8.97%
controls:8.63%
cases:9.01%
controls:5.90%
cases:4.72%
controls:1.28%
—
—
cases:2.62%
controls:0.81%
cases:12.80%
controls:5.64%
cases:23.23%
controls:13.25%
21
202
213
2138
21
138
212
2202
11
30
222
2310
—
6
19
223
2316
27
127
184
2125
36
244
119
1597
Cathetrisation of artery
TPH07 [2001309747]
6.6e-01
—
—
—
1.0e+50
2.9e+00
—
cases:2.14%
controls:1.11%
—
—
—
—
—
—
cases:2.18%
controls:0.00%
cases:7.58%
controls:0.44%
—
—
5
26
229
2314
—
—
—
5
0
224
2335
16
10
195
2242
—
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
1.0e-01
3.8e-01
1.6e+00
—
1.8e+00
1.1e+00
6.3e-01
cases:10.26%
controls:9.36%
cases:8.58%
controls:6.03%
cases:3.43%
controls:0.73%
—
—
cases:3.49%
controls:0.60%
cases:13.27%
controls:4.93%
cases:26.45%
controls:16.13%
24
219
210
2121
20
141
213
2199
8
17
225
2323
—
8
14
221
2321
28
111
183
2141
41
297
114
1544
Pharmacy visit
OMOP4822462 [581458]
2.8e-02
4.3e-01
6.8e-01
8.3e-01
9.3e-01
1.2e+00
9.6e-01
cases:93.59%
controls:93.42%
cases:90.13%
controls:85.56%
cases:67.38%
controls:51.24%
cases:6.87%
controls:3.12%
cases:73.80%
controls:52.63%
cases:95.73%
controls:86.55%
cases:98.06%
controls:95.11%
219
2186
15
154
210
2002
23
338
157
1199
76
1141
16
73
217
2267
169
1229
60
1106
202
1949
9
303
152
1751
3
90
Bacteria identified in Blood by Culture
600-7 [3023368]
2.2e-01
2.0e-01
—
1.0e+50
—
1.7e+00
1.1e+00
cases:5.13%
controls:4.15%
cases:3.43%
controls:2.82%
—
—
cases:2.15%
controls:0.00%
—
—
cases:13.27%
controls:2.71%
cases:21.94%
controls:8.20%
12
97
222
2243
8
66
225
2274
—
5
0
228
2340
—
28
61
183
2191
34
151
121
1690
Redundant prepuce, phimosis and paraphimosis
N47 [45596870]
2.8e+00
—
—
1.0e+50
1.0e+50
—
—
cases:5.56%
controls:0.34%
—
—
—
—
cases:3.86%
controls:0.00%
cases:3.49%
controls:0.00%
—
—
—
—
13
8
221
2332
—
—
9
0
224
2340
8
0
221
2335
—
—
Protein [Presence] in Urine by Test strip
20454-5 [3014051]
7.4e-01
1.0e+00
2.8e+00
—
1.6e+00
8.8e-01
3.1e-01
cases:5.56%
controls:2.74%
cases:5.15%
controls:1.97%
cases:4.72%
controls:0.30%
—
—
cases:2.18%
controls:0.43%
cases:5.21%
controls:2.22%
cases:12.26%
controls:9.29%
13
64
221
2276
12
46
221
2294
11
7
222
2333
—
5
10
224
2325
11
50
200
2202
19
171
136
1670
ABO and Rh group [Type] in Blood by Confirmatory method
77397-8 [46236098]
2.6e-02
3.4e-01
—
1.0e+50
—
2.8e+00
6.9e-01
cases:3.42%
controls:3.33%
cases:2.58%
controls:1.84%
—
—
cases:2.15%
controls:0.00%
—
—
cases:18.01%
controls:1.33%
cases:11.61%
controls:6.19%
8
78
226
2262
6
43
227
2297
—
5
0
228
2340
—
38
30
173
2222
18
114
137
1727
Hemoglobin [Presence] in Urine by Test strip
5794-3 [3011397]
-1.3e-02
—
2.7e+00
—
—
6.5e-01
1.5e-02
cases:3.42%
controls:3.46%
—
—
cases:3.86%
controls:0.26%
—
—
—
—
cases:4.74%
controls:2.53%
cases:9.03%
controls:8.91%
8
81
226
2259
—
9
6
224
2334
—
—
10
57
201
2195
14
164
141
1677
Carboxyhemoglobin/Hemoglobin.total in Arterial blood
2030-5 [3028653]
-1.0e+50
-1.0e+50
—
—
—
2.7e+00
—
cases:0.00%
controls:1.07%
cases:0.00%
controls:0.90%
—
—
—
—
—
—
cases:5.69%
controls:0.40%
—
—
0
25
234
2315
0
21
233
2319
—
—
—
12
9
199
2243
—
Methemoglobin/Hemoglobin.total in Arterial blood
2615-3 [3006217]
-1.0e+50
-1.0e+50
—
—
—
2.7e+00
—
cases:0.00%
controls:1.07%
cases:0.00%
controls:0.85%
—
—
—
—
—
—
cases:5.69%
controls:0.40%
—
—
0
25
234
2315
0
20
233
2320
—
—
—
12
9
199
2243
—
Ultrasound examination of lower leg veins
PH2AE [2001309451]
—
—
—
—
—
2.7e+00
8.2e-01
—
—
—
—
—
—
—
—
—
—
cases:3.79%
controls:0.27%
cases:3.87%
controls:1.74%
—
—
—
—
—
8
6
203
2246
6
32
149
1809
Fractional oxyhemoglobin in Arterial blood
2714-4 [3014007]
-1.0e+50
-1.0e+50
—
—
—
2.7e+00
—
cases:0.00%
controls:1.11%
cases:0.00%
controls:0.90%
—
—
—
—
—
—
cases:6.16%
controls:0.44%
—
—
0
26
234
2314
0
21
233
2319
—
—
—
13
10
198
2242
—
Specific gravity of Urine by Refractometry
5810-7 [3019150]
1.0e-01
-3.6e-02
2.7e+00
—
1.6e+00
4.7e-01
-6.9e-02
cases:4.70%
controls:4.27%
cases:2.15%
controls:2.22%
cases:3.00%
controls:0.21%
—
—
cases:2.62%
controls:0.51%
cases:4.27%
controls:2.71%
cases:9.03%
controls:9.61%
11
100
223
2240
5
52
228
2288
7
5
226
2335
—
6
12
223
2323
9
61
202
2191
14
177
141
1664
Bicarbonate [Moles/volume] in Serum or Plasma
1963-8 [3016293]
—
—
—
—
—
2.6e+00
—
—
—
—
—
—
—
—
—
—
—
cases:4.74%
controls:0.36%
—
—
—
—
—
—
—
10
8
201
2244
—
Spinalanesthesia
WX320 [2001310799]
6.4e-01
8.7e-01
—
1.0e+50
—
2.6e+00
5.9e-01
cases:5.13%
controls:2.78%
cases:3.00%
controls:1.28%
—
—
cases:2.15%
controls:0.00%
—
—
cases:9.95%
controls:0.80%
cases:7.10%
controls:4.07%
12
65
222
2275
7
30
226
2310
—
5
0
228
2340
—
21
18
190
2234
11
75
144
1766
levofloxacin; inhalant, oral, parenteral
J01MA12 [21603019]
1.1e+00
—
—
—
—
1.5e+00
1.0e+00
cases:6.41%
controls:2.22%
—
—
—
—
—
—
—
—
cases:4.27%
controls:0.98%
cases:9.03%
controls:3.42%
15
52
219
2288
—
—
—
—
9
22
202
2230
14
63
141
1778
Calcium [Moles/volume] corrected for albumin in Serum or Plasma
29265-6 [3020059]
—
—
—
—
—
1.4e+00
1.1e+00
—
—
—
—
—
—
—
—
—
—
cases:6.16%
controls:1.55%
cases:11.61%
controls:4.07%
—
—
—
—
—
13
35
198
2217
18
75
137
1766
Neisseria gonorrhoeae DNA [Presence] in Urine by NAA with probe detection
21416-3 [3003510]
—
2.5e+00
—
—
—
—
-1.0e+50
—
—
cases:2.58%
controls:0.21%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.92%
—
6
5
227
2335
—
—
—
—
0
17
155
1824
Enzyme measurement
122444009 [4046263]
—
2.5e+00
—
—
—
—
1.8e+00
—
—
cases:2.58%
controls:0.21%
—
—
—
—
—
—
—
—
cases:3.87%
controls:0.65%
—
6
5
227
2335
—
—
—
—
6
12
149
1829
Cystitis
N30 [45563012]
2.5e+00
—
—
—
—
—
-1.0e+50
cases:2.56%
controls:0.21%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
6
5
228
2335
—
—
—
—
—
0
8
155
1833
Prostate specific Ag [Mass/volume] in Serum or Plasma
2857-1 [3013603]
1.9e-01
5.4e-01
2.5e+00
—
9.6e-01
4.7e-01
2.5e-01
cases:24.79%
controls:21.41%
cases:18.88%
controls:11.97%
cases:12.02%
controls:1.11%
—
—
cases:4.37%
controls:1.71%
cases:19.43%
controls:13.10%
cases:38.71%
controls:32.97%
58
501
176
1839
44
280
189
2060
28
26
205
2314
—
10
40
219
2295
41
295
170
1957
60
607
95
1234
ABO and Rh group [Type] in Blood
882-1 [3003694]
-1.9e-01
—
—
—
—
2.5e+00
4.5e-01
cases:3.42%
controls:4.10%
—
—
—
—
—
—
—
—
cases:12.32%
controls:1.15%
cases:8.39%
controls:5.54%
8
96
226
2244
—
—
—
—
26
26
185
2226
13
102
142
1739
aPTT in Platelet poor plasma by Coagulation assay
14979-9 [3018677]
3.6e-01
—
—
—
—
2.5e+00
6.0e-01
cases:4.27%
controls:3.03%
—
—
—
—
—
—
—
—
cases:9.48%
controls:0.89%
cases:7.10%
controls:4.02%
10
71
224
2269
—
—
—
—
20
20
191
2232
11
74
144
1767
sulfadiazine and trimethoprim
J01EE02 [21602962]
5.8e-01
—
—
—
—
2.4e+00
1.2e+00
cases:3.85%
controls:2.18%
—
—
—
—
—
—
—
—
cases:4.74%
controls:0.44%
cases:5.81%
controls:1.79%
9
51
225
2289
—
—
—
—
10
10
201
2242
9
33
146
1808
General psychiatric examination, not elsewhere classified
Z00.4 [45605094]
—
—
—
—
—
2.4e+00
—
—
—
—
—
—
—
—
—
—
—
cases:2.37%
controls:0.22%
—
—
—
—
—
—
—
5
5
206
2247
—
carbamide
D02AE01 [21601975]
—
—
—
—
—
—
2.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.87%
controls:0.38%
—
—
—
—
—
—
6
7
149
1834
Pure hypercholesterolaemia
E78.01 [2000501514]
3.6e-01
—
—
—
2.3e+00
8.5e-01
6.8e-02
cases:6.84%
controls:4.87%
—
—
—
—
—
—
cases:2.18%
controls:0.21%
cases:4.74%
controls:2.09%
cases:8.39%
controls:7.88%
16
114
218
2226
—
—
—
5
5
224
2330
10
47
201
2205
13
145
142
1696
Prostate Specific Ag Free/Prostate specific Ag.total in Serum or Plasma
12841-3 [3001784]
1.6e-02
3.0e-01
2.3e+00
—
9.9e-01
2.9e-02
6.8e-02
cases:16.24%
controls:16.03%
cases:11.16%
controls:8.55%
cases:7.30%
controls:0.77%
—
—
cases:2.62%
controls:0.99%
cases:9.48%
controls:9.24%
cases:25.16%
controls:23.90%
38
375
196
1965
26
200
207
2140
17
18
216
2322
—
6
23
223
2312
20
208
191
2044
39
440
116
1401
Catheterisation of bladder
TKC20 [2001306020]
—
-1.0e+50
—
—
—
2.3e+00
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
cases:4.27%
controls:0.44%
—
—
—
0
9
233
2331
—
—
—
9
10
202
2242
—
Prostate Specific Ag Free [Mass/volume] in Serum or Plasma
10886-0 [3005013]
1.2e-01
3.6e-01
2.3e+00
—
—
-7.5e-02
1.7e-02
cases:11.11%
controls:10.00%
cases:7.30%
controls:5.21%
cases:4.72%
controls:0.51%
—
—
—
—
cases:5.21%
controls:5.60%
cases:15.48%
controls:15.26%
26
234
208
2106
17
122
216
2218
11
12
222
2328
—
—
11
126
200
2126
24
281
131
1560
General Practice
1 [38004446]
3.4e-02
-2.0e-02
1.1e+00
—
1.4e+00
8.1e-01
5.2e-01
cases:17.09%
controls:16.62%
cases:7.30%
controls:7.44%
cases:3.43%
controls:1.20%
—
—
cases:4.80%
controls:1.24%
cases:15.64%
controls:7.64%
cases:30.97%
controls:21.08%
40
389
194
1951
17
174
216
2166
8
28
225
2312
—
11
29
218
2306
33
172
178
2080
48
388
107
1453
Retention of urine
R33 [45587507]
—
—
—
—
—
2.2e+00
1.2e+00
—
—
—
—
—
—
—
—
—
—
cases:5.69%
controls:0.67%
cases:6.45%
controls:1.96%
—
—
—
—
—
12
15
199
2237
10
36
145
1805
pH of Serum or Plasma
2753-2 [3018418]
2.8e-01
4.3e-01
—
—
2.2e+00
7.5e-01
5.3e-01
cases:6.84%
controls:5.26%
cases:4.72%
controls:3.12%
—
—
—
—
cases:2.62%
controls:0.30%
cases:6.16%
controls:3.02%
cases:14.19%
controls:8.91%
16
123
218
2217
11
73
222
2267
—
—
6
7
223
2328
13
68
198
2184
22
164
133
1677
HIV 1 and 2 tests - Meaningful Use set
75622-1 [46235355]
2.1e-01
7.4e-01
—
—
—
2.2e+00
9.2e-01
cases:2.56%
controls:2.09%
cases:2.58%
controls:1.24%
—
—
—
—
—
—
cases:3.79%
controls:0.44%
cases:5.16%
controls:2.12%
6
49
228
2291
6
29
227
2311
—
—
—
8
10
203
2242
8
39
147
1802
Lactate [Moles/volume] in Serum or Plasma
2524-7 [3014111]
—
-1.0e+50
—
—
—
2.2e+00
5.9e-01
—
—
cases:0.00%
controls:1.11%
—
—
—
—
—
—
cases:6.64%
controls:0.80%
cases:5.81%
controls:3.31%
—
0
26
233
2314
—
—
—
14
18
197
2234
9
61
146
1780
Suture or treatment of traumatic wound
SPAT1149 [2001700250]
—
—
—
—
—
2.1e+00
9.2e-01
—
—
—
—
—
—
—
—
—
—
cases:4.74%
controls:0.58%
cases:5.81%
controls:2.39%
—
—
—
—
—
10
13
201
2239
9
44
146
1797
Gas panel - Venous blood
24339-4 [3000991]
—
—
—
—
—
2.1e+00
-6.1e-02
—
—
—
—
—
—
—
—
—
—
cases:8.06%
controls:1.02%
cases:3.23%
controls:3.42%
—
—
—
—
—
17
23
194
2229
5
63
150
1778
clindamycin; oral, parenteral
J01FF01 [21602985]
3.8e-01
—
—
—
—
2.1e+00
2.5e-01
cases:4.70%
controls:3.25%
—
—
—
—
—
—
—
—
cases:8.06%
controls:1.02%
cases:3.87%
controls:3.04%
11
76
223
2264
—
—
—
—
17
23
194
2229
6
56
149
1785
Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction
14804-9 [3022250]
1.8e-01
7.1e-01
—
—
—
2.1e+00
1.1e+00
cases:2.14%
controls:1.79%
cases:2.15%
controls:1.07%
—
—
—
—
—
—
cases:5.69%
controls:0.71%
cases:7.74%
controls:2.61%
5
42
229
2298
5
25
228
2315
—
—
—
12
16
199
2236
12
48
143
1793
Removal of sutures
SPAT1153 [2001700254]
1.4e-01
5.8e-01
—
—
—
2.1e+00
3.8e-01
cases:6.41%
controls:5.64%
cases:3.00%
controls:1.71%
—
—
—
—
—
—
cases:7.58%
controls:0.98%
cases:7.10%
controls:4.94%
15
132
219
2208
7
40
226
2300
—
—
—
16
22
195
2230
11
91
144
1750
Intravenous administration of medicine
SPAT1255 [2001700356]
1.0e+00
—
—
—
—
2.1e+00
1.6e+00
cases:2.14%
controls:0.77%
—
—
—
—
—
—
—
—
cases:2.84%
controls:0.36%
cases:4.52%
controls:0.92%
5
18
229
2322
—
—
—
—
6
8
205
2244
7
17
148
1824
Treatment of chronic ulcer or burn
SPAT1148 [2001700249]
-2.0e-02
—
—
—
—
2.1e+00
8.5e-01
cases:2.14%
controls:2.18%
—
—
—
—
—
—
—
—
cases:5.21%
controls:0.67%
cases:7.10%
controls:3.15%
5
51
229
2289
—
—
—
—
11
15
200
2237
11
58
144
1783
Palliative care
Z51.5 [45547323]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.87%
controls:0.49%
—
—
—
—
—
—
6
9
149
1832
One hour or less
ZXE00 [2001311394]
4.2e-01
1.2e+00
—
1.0e+50
—
2.1e+00
8.2e-01
cases:8.12%
controls:5.51%
cases:4.72%
controls:1.45%
—
—
cases:2.58%
controls:0.00%
—
—
cases:9.00%
controls:1.20%
cases:9.03%
controls:4.18%
19
129
215
2211
11
34
222
2306
—
6
0
227
2340
—
19
27
192
2225
14
77
141
1764
Bacteria identified in Isolate by Culture
43409-2 [3042936]
1.7e-02
6.3e-01
—
—
—
2.1e+00
6.5e-01
cases:2.56%
controls:2.52%
cases:2.15%
controls:1.15%
—
—
—
—
—
—
cases:9.00%
controls:1.20%
cases:8.39%
controls:4.56%
6
59
228
2281
5
27
228
2313
—
—
—
19
27
192
2225
13
84
142
1757
Hepatitis B virus surface Ag [Presence] in Serum
5195-3 [3019284]
—
9.8e-01
—
—
—
2.1e+00
1.2e+00
—
—
cases:2.58%
controls:0.98%
—
—
—
—
—
—
cases:3.79%
controls:0.49%
cases:5.81%
controls:1.74%
—
6
23
227
2317
—
—
—
8
11
203
2241
9
32
146
1809
Oxygen saturation in Arterial blood
2708-6 [3016502]
—
—
—
—
—
2.1e+00
1.4e-01
—
—
—
—
—
—
—
—
—
—
cases:5.69%
controls:0.75%
cases:3.87%
controls:3.37%
—
—
—
—
—
12
17
199
2235
6
62
149
1779
Magnesium [Moles/volume] in Serum or Plasma
2601-3 [3012095]
3.5e-01
—
—
—
—
2.1e+00
7.8e-01
cases:2.99%
controls:2.14%
—
—
—
—
—
—
—
—
cases:8.06%
controls:1.11%
cases:7.10%
controls:3.37%
7
50
227
2290
—
—
—
—
17
25
194
2227
11
62
144
1779
Physiotherapy
R4110 [2001310233]
-5.1e-02
3.7e-01
—
—
—
2.0e+00
3.7e-01
cases:4.27%
controls:4.49%
cases:2.15%
controls:1.50%
—
—
—
—
—
—
cases:10.43%
controls:1.51%
cases:7.10%
controls:5.00%
10
105
224
2235
5
35
228
2305
—
—
—
22
34
189
2218
11
92
144
1749
EKG study
11524-6 [3013512]
1.0e-01
5.5e-01
2.0e+00
—
1.6e+00
8.4e-01
1.9e-01
cases:7.69%
controls:7.01%
cases:7.30%
controls:4.36%
cases:3.43%
controls:0.47%
—
—
cases:3.49%
controls:0.73%
cases:9.95%
controls:4.57%
cases:15.48%
controls:13.15%
18
164
216
2176
17
102
216
2238
8
11
225
2329
—
8
17
221
2318
21
103
190
2149
24
242
131
1599
Hemoglobin [Mass/volume] in Arterial blood
30313-1 [3002173]
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
cases:5.69%
controls:0.80%
—
—
—
—
—
—
—
12
18
199
2234
—
Internal Medicine
11 [38004456]
5.9e-02
1.7e-01
1.3e+00
1.0e+50
7.0e-01
6.0e-01
6.6e-01
cases:26.92%
controls:25.77%
cases:12.02%
controls:10.30%
cases:4.72%
controls:1.28%
cases:4.72%
controls:0.00%
cases:3.06%
controls:1.54%
cases:16.59%
controls:9.86%
cases:36.13%
controls:22.65%
63
603
171
1737
28
241
205
2099
11
30
222
2310
11
0
222
2340
7
36
222
2299
35
222
176
2030
56
417
99
1424
Biopsy of skin and subcutaneous tissue
TQX10 [2001310152]
1.6e+00
—
—
—
—
—
2.0e+00
cases:2.56%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
cases:3.87%
controls:0.54%
6
12
228
2328
—
—
—
—
—
6
10
149
1831
Other chronic renal failure
N18.8 [45534123]
—
2.3e+00
—
—
—
—
2.0e+00
—
—
cases:2.15%
controls:0.21%
—
—
—
—
—
—
—
—
cases:3.87%
controls:0.54%
—
5
5
228
2335
—
—
—
—
6
10
149
1831
INR in Blood by Coagulation assay
34714-6 [3032080]
2.2e-01
-4.6e-02
6.7e-01
—
8.9e-01
1.3e+00
7.0e-01
cases:14.96%
controls:12.39%
cases:8.15%
controls:8.50%
cases:5.58%
controls:2.95%
—
—
cases:6.11%
controls:2.61%
cases:23.70%
controls:7.95%
cases:30.32%
controls:17.71%
35
290
199
2050
19
199
214
2141
13
69
220
2271
—
14
61
215
2274
50
179
161
2073
47
326
108
1515
pH of Arterial blood
2744-1 [3019977]
—
—
—
—
—
2.0e+00
2.7e-01
—
—
—
—
—
—
—
—
—
—
cases:5.69%
controls:0.84%
cases:4.52%
controls:3.48%
—
—
—
—
—
12
19
199
2233
7
64
148
1777
Laceration/cut
S18 [2002000983]
5.5e-03
6.4e-01
—
—
1.9e+00
2.0e+00
3.9e-01
cases:8.55%
controls:8.50%
cases:6.01%
controls:3.25%
—
—
—
—
cases:2.18%
controls:0.34%
cases:17.54%
controls:2.93%
cases:16.13%
controls:11.52%
20
199
214
2141
14
76
219
2264
—
—
5
8
224
2327
37
66
174
2186
25
212
130
1629
Erysipelas
A46 [45561706]
2.1e-01
—
—
—
—
1.9e+00
1.0e+00
cases:2.56%
controls:2.09%
—
—
—
—
—
—
—
—
cases:5.21%
controls:0.80%
cases:9.03%
controls:3.42%
6
49
228
2291
—
—
—
—
11
18
200
2234
14
63
141
1778
Base excess in Arterial blood by calculation
1925-7 [3003396]
—
—
—
—
—
1.9e+00
3.8e-01
—
—
—
—
—
—
—
—
—
—
cases:5.69%
controls:0.89%
cases:5.16%
controls:3.59%
—
—
—
—
—
12
20
199
2232
8
66
147
1775
Carbon dioxide [Partial pressure] in Arterial blood
2019-8 [3027946]
—
—
—
—
—
1.9e+00
3.3e-01
—
—
—
—
—
—
—
—
—
—
cases:5.69%
controls:0.89%
cases:5.16%
controls:3.75%
—
—
—
—
—
12
20
199
2232
8
69
147
1772
Oxygen [Partial pressure] in Arterial blood
2703-7 [3027801]
—
—
—
—
—
1.9e+00
3.3e-01
—
—
—
—
—
—
—
—
—
—
cases:5.69%
controls:0.89%
cases:5.16%
controls:3.75%
—
—
—
—
—
12
20
199
2232
8
69
147
1772
Chloride [Moles/volume] in Serum or Plasma
2075-0 [3014576]
4.2e-02
—
—
—
—
1.8e+00
2.8e-01
cases:2.14%
controls:2.05%
—
—
—
—
—
—
—
—
cases:9.00%
controls:1.55%
cases:5.81%
controls:4.45%
5
48
229
2292
—
—
—
—
19
35
192
2217
9
82
146
1759
Observation for suspected disease or condition, unspecified
Z03.9 [45552062]
7.7e-01
—
—
—
—
1.8e+00
6.8e-01
cases:5.56%
controls:2.65%
—
—
—
—
—
—
—
—
cases:4.27%
controls:0.71%
cases:5.81%
controls:3.04%
13
62
221
2278
—
—
—
—
9
16
202
2236
9
56
146
1785
Oxygen capacity [Volume Fraction] in Arterial blood
59275-8 [40762366]
—
—
—
—
—
1.8e+00
—
—
—
—
—
—
—
—
—
—
—
cases:3.32%
controls:0.58%
—
—
—
—
—
—
—
7
13
204
2239
—
lorazepam; oral, parenteral, sublingual
N05BA06 [21604571]
—
—
—
—
—
1.8e+00
—
—
—
—
—
—
—
—
—
—
—
cases:3.79%
controls:0.67%
—
—
—
—
—
—
—
8
15
203
2237
—
Hyaline casts [#/volume] in Urine by Automated count
51484-4 [3030981]
—
1.5e+00
—
—
—
1.8e+00
8.2e-01
—
—
cases:3.00%
controls:0.68%
—
—
—
—
—
—
cases:4.74%
controls:0.84%
cases:6.45%
controls:2.93%
—
7
16
226
2324
—
—
—
10
19
201
2233
10
54
145
1787
Cathetrisation of vein
TPH04 [2001309597]
3.5e-02
4.7e-01
—
—
—
1.8e+00
5.7e-01
cases:2.56%
controls:2.48%
cases:2.58%
controls:1.62%
—
—
—
—
—
—
cases:5.69%
controls:1.02%
cases:5.81%
controls:3.37%
6
58
228
2282
6
38
227
2302
—
—
—
12
23
199
2229
9
62
146
1779
Benign neoplasm: Colon, unspecified
D12.6 [45576377]
—
-1.0e+50
—
—
—
-1.0e+50
1.7e+00
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
cases:0.00%
controls:0.36%
cases:4.52%
controls:0.81%
—
0
7
233
2333
—
—
—
0
8
211
2244
7
15
148
1826
Office Visit
OMOP4822458 [581477]
5.6e-01
3.9e-01
—
—
2.0e+00
1.7e+00
7.0e-01
cases:14.10%
controls:8.59%
cases:3.43%
controls:2.35%
—
—
—
—
cases:2.18%
controls:0.30%
cases:9.95%
controls:1.91%
cases:10.97%
controls:5.76%
33
201
201
2139
8
55
225
2285
—
—
5
7
224
2328
21
43
190
2209
17
106
138
1735
Unspecified haematuria
R31 [45553726]
1.0e+00
1.7e+00
—
—
—
—
9.5e-01
cases:3.42%
controls:1.28%
cases:3.43%
controls:0.64%
—
—
—
—
—
—
—
—
cases:5.81%
controls:2.34%
8
30
226
2310
8
15
225
2325
—
—
—
—
9
43
146
1798
Monocytes [#/volume] in Blood
26484-6 [3001604]
1.3e-01
5.3e-01
1.2e+00
—
1.1e+00
9.5e-01
7.2e-01
cases:10.26%
controls:9.10%
cases:10.30%
controls:6.32%
cases:4.29%
controls:1.32%
—
—
cases:2.62%
controls:0.90%
cases:14.22%
controls:6.04%
cases:25.16%
controls:14.07%
24
213
210
2127
24
148
209
2192
10
31
223
2309
—
6
21
223
2314
30
136
181
2116
39
259
116
1582
Basophils [#/volume] in Blood
26444-0 [3006315]
1.3e-01
5.2e-01
1.2e+00
—
1.0e+00
9.4e-01
7.2e-01
cases:10.26%
controls:9.10%
cases:10.30%
controls:6.37%
cases:4.29%
controls:1.32%
—
—
cases:2.62%
controls:0.94%
cases:14.22%
controls:6.08%
cases:25.16%
controls:14.12%
24
213
210
2127
24
149
209
2191
10
31
223
2309
—
6
22
223
2313
30
137
181
2115
39
260
116
1581
Bilateral
ZXA10 [2001311348]
5.9e-02
—
—
—
—
1.7e+00
—
cases:3.85%
controls:3.63%
—
—
—
—
—
—
—
—
cases:4.27%
controls:0.84%
—
—
9
85
225
2255
—
—
—
—
9
19
202
2233
—
Emergency Medicine
93 [38004510]
1.5e-01
2.2e-01
1.6e+00
1.0e+50
1.4e+00
6.4e-01
4.0e-01
cases:15.38%
controls:13.55%
cases:9.44%
controls:7.69%
cases:4.29%
controls:0.85%
cases:3.86%
controls:0.00%
cases:2.62%
controls:0.64%
cases:14.69%
controls:8.30%
cases:33.55%
controls:25.26%
36
317
198
2023
22
180
211
2160
10
20
223
2320
9
0
224
2340
6
15
223
2320
31
187
180
2065
52
465
103
1376
prednisolone; oral, parenteral
H02AB06 [21602734]
4.2e-01
3.6e-01
7.5e-01
—
—
8.7e-01
7.8e-01
cases:14.96%
controls:10.38%
cases:6.44%
controls:4.57%
cases:2.15%
controls:1.03%
—
—
—
—
cases:11.37%
controls:5.11%
cases:22.58%
controls:11.84%
35
243
199
2097
15
107
218
2233
5
24
228
2316
—
—
24
115
187
2137
35
218
120
1623
Chronic kidney disease, unspecified
N18.9 [45553438]
—
—
—
—
—
1.6e+00
5.5e-01
—
—
—
—
—
—
—
—
—
—
cases:3.79%
controls:0.75%
cases:4.52%
controls:2.66%
—
—
—
—
—
8
17
203
2235
7
49
148
1792
prednisolone
A07EA01 [21600653]
4.2e-01
3.5e-01
7.5e-01
—
—
8.7e-01
7.7e-01
cases:14.96%
controls:10.38%
cases:6.44%
controls:4.62%
cases:2.15%
controls:1.03%
—
—
—
—
cases:11.37%
controls:5.11%
cases:22.58%
controls:11.90%
35
243
199
2097
15
108
218
2232
5
24
228
2316
—
—
24
115
187
2137
35
219
120
1622
Lymphocytes [#/volume] in Blood
26474-7 [3019198]
9.1e-02
5.2e-01
1.2e+00
—
1.0e+00
9.3e-01
6.8e-01
cases:10.26%
controls:9.44%
cases:10.30%
controls:6.41%
cases:4.29%
controls:1.32%
—
—
cases:2.62%
controls:0.94%
cases:14.22%
controls:6.13%
cases:25.16%
controls:14.50%
24
221
210
2119
24
150
209
2190
10
31
223
2309
—
6
22
223
2313
30
138
181
2114
39
267
116
1574
hydrocortisone; local oral
A01AC03 [21600036]
8.0e-01
—
—
—
—
—
1.6e+00
cases:2.99%
controls:1.37%
—
—
—
—
—
—
—
—
—
—
cases:5.16%
controls:1.09%
7
32
227
2308
—
—
—
—
—
8
20
147
1821
trimethoprim; oral, parenteral
J01EA01 [21602931]
9.2e-01
1.4e+00
—
—
—
1.6e+00
1.1e+00
cases:4.27%
controls:1.75%
cases:3.43%
controls:0.90%
—
—
—
—
—
—
cases:5.21%
controls:1.11%
cases:7.74%
controls:2.66%
10
41
224
2299
8
21
225
2319
—
—
—
11
25
200
2227
12
49
143
1792
Eosinophils [#/volume] in Blood
26449-9 [3013115]
1.2e-01
5.3e-01
1.2e+00
—
1.3e+00
8.9e-01
7.0e-01
cases:10.68%
controls:9.62%
cases:10.73%
controls:6.58%
cases:4.72%
controls:1.41%
—
—
cases:3.49%
controls:0.94%
cases:14.22%
controls:6.39%
cases:25.81%
controls:14.77%
25
225
209
2115
25
154
208
2186
11
33
222
2307
—
8
22
221
2313
30
144
181
2108
40
272
115
1569
Abnormal findings on diagnostic imaging of lung
R91 [45548995]
—
-1.0e+50
—
—
—
—
1.6e+00
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
cases:5.81%
controls:1.25%
—
0
11
233
2329
—
—
—
—
9
23
146
1818
Aid fitting and borrowing and monitoring of use
SPAT1230 [2001700331]
-2.5e-01
—
—
—
—
1.5e+00
-2.8e-01
cases:2.14%
controls:2.74%
—
—
—
—
—
—
—
—
cases:5.21%
controls:1.20%
cases:3.23%
controls:4.24%
5
64
229
2276
—
—
—
—
11
27
200
2225
5
78
150
1763
Physical Medicine And Rehabilitation
25 [38004468]
-3.6e-01
—
—
—
—
1.5e+00
-2.1e-02
cases:3.85%
controls:5.43%
—
—
—
—
—
—
—
—
cases:5.69%
controls:1.33%
cases:5.81%
controls:5.92%
9
127
225
2213
—
—
—
—
12
30
199
2222
9
109
146
1732
Prealbumin [Mass/volume] in Serum or Plasma
14338-8 [3013742]
—
—
—
—
—
—
1.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.45%
controls:1.58%
—
—
—
—
—
—
10
29
145
1812
Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]
1.1e-01
1.9e-01
1.4e+00
—
—
6.0e-01
5.6e-01
cases:18.80%
controls:17.18%
cases:9.87%
controls:8.29%
cases:5.15%
controls:1.28%
—
—
—
—
cases:14.22%
controls:8.35%
cases:37.42%
controls:25.53%
44
402
190
1938
23
194
210
2146
12
30
221
2310
—
—
30
188
181
2064
58
470
97
1371
Psychiatry
26 [38004469]
-2.9e-02
—
—
—
—
1.4e+00
1.2e-01
cases:2.99%
controls:3.08%
—
—
—
—
—
—
—
—
cases:4.74%
controls:1.24%
cases:3.23%
controls:2.88%
7
72
227
2268
—
—
—
—
10
28
201
2224
5
53
150
1788
pantoprazole; oral, parenteral
A02BC02 [21600097]
-6.5e-02
1.7e-01
-2.8e-01
—
1.3e+00
5.4e-01
4.3e-01
cases:16.24%
controls:17.14%
cases:12.02%
controls:10.34%
cases:2.15%
controls:2.82%
—
—
cases:7.42%
controls:2.18%
cases:17.06%
controls:10.75%
cases:29.68%
controls:21.46%
38
401
196
1939
28
242
205
2098
5
66
228
2274
—
17
51
212
2284
36
242
175
2010
46
395
109
1446
imidazoles/triazoles in combination with corticosteroids
D01AC20 [21601936]
3.4e-01
1.3e+00
-1.0e+50
—
—
5.1e-01
-4.2e-01
cases:6.41%
controls:4.66%
cases:6.01%
controls:1.75%
cases:0.00%
controls:0.21%
—
—
—
—
cases:2.84%
controls:1.73%
cases:3.23%
controls:4.83%
15
109
219
2231
14
41
219
2299
0
5
233
2335
—
—
6
39
205
2213
5
89
150
1752
pH of Specimen
17433-4 [3019225]
—
1.1e+00
—
—
—
1.8e+00
1.3e+00
—
—
cases:2.58%
controls:0.85%
—
—
—
—
—
—
cases:2.84%
controls:0.49%
cases:8.39%
controls:2.50%
—
6
20
227
2320
—
—
—
6
11
205
2241
13
46
142
1795
Phosphate [Moles/volume] in Serum or Plasma
14879-1 [3003458]
2.7e-01
1.3e-01
—
—
—
1.3e+00
9.2e-01
cases:3.85%
controls:2.95%
cases:2.58%
controls:2.26%
—
—
—
—
—
—
cases:6.64%
controls:1.95%
cases:10.32%
controls:4.40%
9
69
225
2271
6
53
227
2287
—
—
—
14
44
197
2208
16
81
139
1760
Infiltration anesthesia
WX110 [2001310767]
1.5e-01
1.4e-01
—
1.0e+50
—
1.2e+00
-9.4e-02
cases:19.66%
controls:17.39%
cases:8.15%
controls:7.18%
—
—
cases:3.00%
controls:0.00%
—
—
cases:19.91%
controls:6.71%
cases:19.35%
controls:20.86%
46
407
188
1933
19
168
214
2172
—
7
0
226
2340
—
42
151
169
2101
30
384
125
1457
Emergency Room and Inpatient Visit
ERIP [262]
2.9e-01
3.2e-01
—
1.0e+50
—
1.2e+00
4.2e-01
cases:5.13%
controls:3.89%
cases:4.29%
controls:3.16%
—
—
cases:3.86%
controls:0.00%
—
—
cases:9.95%
controls:3.33%
cases:16.77%
controls:11.73%
12
91
222
2249
10
74
223
2266
—
9
0
224
2340
—
21
75
190
2177
26
216
129
1625
Sampling
SPAT1263 [2001700364]
3.3e-01
6.1e-01
1.1e+00
—
1.4e+00
1.2e+00
2.8e-01
cases:11.97%
controls:8.93%
cases:5.58%
controls:3.12%
cases:2.15%
controls:0.73%
—
—
cases:2.62%
controls:0.69%
cases:11.37%
controls:3.86%
cases:12.90%
controls:10.05%
28
209
206
2131
13
73
220
2267
5
17
228
2323
—
6
16
223
2319
24
87
187
2165
20
185
135
1656
Amylase [Enzymatic activity/volume] in Serum or Plasma
1798-8 [3016771]
2.8e-01
1.3e-01
—
—
—
1.2e+00
5.3e-01
cases:6.41%
controls:4.91%
cases:3.00%
controls:2.65%
—
—
—
—
—
—
cases:7.11%
controls:2.35%
cases:14.84%
controls:9.29%
15
115
219
2225
7
62
226
2278
—
—
—
15
53
196
2199
23
171
132
1670
Coloscopy
UJF32 [2001305029]
1.1e+00
—
—
—
—
—
5.7e-01
cases:8.97%
controls:3.21%
—
—
—
—
—
—
—
—
—
—
cases:7.10%
controls:4.13%
21
75
213
2265
—
—
—
—
—
11
76
144
1765
hydrocortisone
S02BA01 [21605166]
1.7e-01
1.1e+00
—
—
—
6.9e-01
4.5e-01
cases:7.26%
controls:6.20%
cases:6.01%
controls:2.18%
—
—
—
—
—
—
cases:3.32%
controls:1.69%
cases:9.03%
controls:5.98%
17
145
217
2195
14
51
219
2289
—
—
—
7
38
204
2214
14
110
141
1731
Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1920-8 [3013721]
2.9e-01
1.8e-01
—
—
—
1.1e+00
6.0e-01
cases:8.55%
controls:6.54%
cases:3.86%
controls:3.25%
—
—
—
—
—
—
cases:8.06%
controls:2.98%
cases:15.48%
controls:9.13%
20
153
214
2187
9
76
224
2264
—
—
—
17
67
194
2185
24
168
131
1673
Influenza virus A RNA [Presence] in Specimen by NAA with probe detection
34487-9 [3044938]
8.1e-01
—
—
—
—
1.1e+00
1.0e+00
cases:3.85%
controls:1.75%
—
—
—
—
—
—
—
—
cases:3.32%
controls:1.15%
cases:12.26%
controls:4.73%
9
41
225
2299
—
—
—
—
7
26
204
2226
19
87
136
1754
combinations of corticosteroids
D07XB30 [21602188]
5.5e-01
1.0e+00
1.6e+00
—
—
8.1e-01
3.5e-01
cases:17.52%
controls:10.90%
cases:12.02%
controls:4.66%
cases:2.58%
controls:0.56%
—
—
—
—
cases:8.53%
controls:4.00%
cases:15.48%
controls:11.46%
41
255
193
2085
28
109
205
2231
6
13
227
2327
—
—
18
90
193
2162
24
211
131
1630
combinations of corticosteroids
D07AB30 [21602118]
5.5e-01
1.0e+00
1.6e+00
—
—
8.1e-01
3.5e-01
cases:17.52%
controls:10.90%
cases:12.02%
controls:4.66%
cases:2.58%
controls:0.56%
—
—
—
—
cases:8.53%
controls:4.00%
cases:15.48%
controls:11.46%
41
255
193
2085
28
109
205
2231
6
13
227
2327
—
—
18
90
193
2162
24
211
131
1630
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]
3.7e-03
-1.3e-01
1.0e+00
—
7.0e-01
3.8e-01
2.7e-01
cases:35.90%
controls:35.81%
cases:24.89%
controls:27.31%
cases:10.30%
controls:3.97%
—
—
cases:8.73%
controls:4.54%
cases:35.55%
controls:27.31%
cases:60.65%
controls:54.05%
84
838
150
1502
58
639
175
1701
24
93
209
2247
—
20
106
209
2229
75
615
136
1637
94
995
61
846
Erythrocytes [Presence] in Urine by Automated
53292-9 [3041096]
7.3e-01
1.0e+00
—
—
1.9e+00
9.8e-01
6.2e-01
cases:8.55%
controls:4.32%
cases:6.87%
controls:2.61%
—
—
—
—
cases:2.62%
controls:0.39%
cases:7.11%
controls:2.80%
cases:14.84%
controls:8.58%
20
101
214
2239
16
61
217
2279
—
—
6
9
223
2326
15
63
196
2189
23
158
132
1683
Intramuscular and subcutaneous injection
SPAT1256 [2001700357]
2.4e-01
6.8e-01
9.3e-01
—
1.4e+00
1.0e+00
5.5e-01
cases:11.11%
controls:8.93%
cases:9.01%
controls:4.79%
cases:2.15%
controls:0.85%
—
—
cases:2.62%
controls:0.69%
cases:9.95%
controls:3.91%
cases:18.06%
controls:11.24%
26
209
208
2131
21
112
212
2228
5
20
228
2320
—
6
16
223
2319
21
88
190
2164
28
207
127
1634
Differential panel, method unspecified - Blood
69738-3 [42870588]
4.8e-01
5.1e-01
1.4e+00
—
1.7e+00
8.2e-01
9.5e-01
cases:8.97%
controls:5.73%
cases:6.87%
controls:4.23%
cases:3.86%
controls:0.94%
—
—
cases:3.06%
controls:0.56%
cases:9.00%
controls:4.17%
cases:18.06%
controls:7.88%
21
134
213
2206
16
99
217
2241
9
22
224
2318
—
7
13
222
2322
19
94
192
2158
28
145
127
1696
Pulmonary Disease
29 [38004472]
2.5e-01
4.0e-01
—
—
9.9e-01
7.8e-01
8.3e-01
cases:13.25%
controls:10.64%
cases:8.58%
controls:5.94%
—
—
—
—
cases:2.62%
controls:0.99%
cases:11.37%
controls:5.55%
cases:24.52%
controls:12.38%
31
249
203
2091
20
139
213
2201
—
—
6
23
223
2312
24
125
187
2127
38
228
117
1613
furosemide; oral, parenteral
C03CA01 [21601518]
1.1e-01
1.5e-01
5.7e-01
—
4.5e-01
8.2e-01
4.5e-01
cases:10.68%
controls:9.66%
cases:9.87%
controls:8.63%
cases:3.86%
controls:2.22%
—
—
cases:4.80%
controls:3.13%
cases:18.48%
controls:9.06%
cases:21.94%
controls:15.15%
25
226
209
2114
23
202
210
2138
9
52
224
2288
—
11
73
218
2262
39
204
172
2048
34
279
121
1562
Spondylolisthesis
M43.1 [45606219]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
0
8
234
2332
—
—
—
—
—
0
9
155
1832
Bilateral inguinal hernia, without obstruction or gangrene
K40.2 [45596320]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.22%
cases:0.00%
controls:0.81%
—
—
—
—
—
0
5
211
2247
0
15
155
1826
betamethasone
C05AA05 [21601610]
-6.2e-02
4.7e-01
-1.0e+50
—
—
2.3e-01
4.8e-01
cases:7.26%
controls:7.69%
cases:4.72%
controls:2.99%
cases:0.00%
controls:0.30%
—
—
—
—
cases:3.32%
controls:2.66%
cases:12.26%
controls:7.98%
17
180
217
2160
11
70
222
2270
0
7
233
2333
—
—
7
60
204
2192
19
147
136
1694
Dulaglutide, exenatide, liraglutide, lixisenatide and semaglutide (adults)
285 [2001600217]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.81%
—
—
—
—
—
—
—
—
—
—
—
—
0
19
234
2321
—
—
—
—
—
—
Implementation of occupational therapy rehabilitation plan
SPAT1226 [2001700327]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
0
5
155
1836
Spermatocele
N43.4 [45558155]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
234
2331
—
—
—
—
—
—
Noninfective gastroenteritis and colitis, unspecified
K52.9 [45572215]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.21%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
234
2335
—
—
—
—
—
—
Multidisciplinary treatment meeting
WZC20 [2001310890]
—
—
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:2.37%
controls:0.00%
—
—
—
—
—
—
—
5
0
206
2252
—
Hemoglobin A1c/Hemoglobin.total in Blood
4548-4 [3004410]
3.2e-02
-6.5e-02
8.0e-01
—
4.8e-01
-1.1e-01
3.4e-02
cases:28.63%
controls:27.99%
cases:20.17%
controls:21.24%
cases:5.15%
controls:2.39%
—
—
cases:5.24%
controls:3.30%
cases:19.91%
controls:21.76%
cases:45.81%
controls:44.98%
67
655
167
1685
47
497
186
1843
12
56
221
2284
—
12
77
217
2258
42
490
169
1762
71
828
84
1013
Open wound of scalp
S01.0 [45592468]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.84%
—
—
—
—
—
—
—
0
19
211
2233
—
trimipramine; oral, parenteral
N06AA06 [21604693]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
0
7
234
2333
—
—
—
—
—
0
6
155
1835
solifenacin; oral
G04BD08 [21602641]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.94%
—
—
—
—
—
—
—
—
—
—
—
—
0
22
234
2318
—
—
—
—
—
—
vilanterol, umeclidinium bromide and fluticasone furoate
R03AL08 [1501769]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.21%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
234
2335
—
—
—
—
—
—
chloramphenicol
D10AF03 [21602307]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.26%
—
—
—
—
—
—
cases:0.00%
controls:0.22%
—
—
—
0
6
233
2334
—
—
—
0
5
211
2247
—
electrolytes
B05BB01 [21601161]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
234
2331
—
—
—
—
—
—
Inspection, maintenance and instruction for use of hearing aid
SPAT1352 [2001700453]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
0
7
233
2333
—
—
—
—
0
7
155
1834
Post COVID-19 condition
U09 [710708]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
0
5
155
1836
Reagin Ab [Titer] in Serum by VDRL
50690-7 [3029634]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
0
9
155
1832
Emergency procedure
ZXD00 [2001311385]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
0
9
234
2331
—
—
—
—
—
0
5
155
1836
Syncope and collapse
R55 [45568141]
3.2e-01
—
—
—
—
—
8.5e-01
cases:2.56%
controls:1.88%
—
—
—
—
—
—
—
—
—
—
cases:5.16%
controls:2.28%
6
44
228
2296
—
—
—
—
—
8
42
147
1799
Epstein Barr virus nuclear IgG Ab [Units/volume] in Serum
31374-2 [3007080]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.21%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
234
2335
—
—
—
—
—
—
Asthma
J45 [45596282]
3.9e-01
—
—
—
—
—
4.1e-01
cases:2.99%
controls:2.05%
—
—
—
—
—
—
—
—
—
—
cases:3.23%
controls:2.17%
7
48
227
2292
—
—
—
—
—
5
40
150
1801
Stomach Pathology biopsy report
66114-0 [40768797]
2.5e-01
—
—
—
—
—
-1.1e-02
cases:2.99%
controls:2.35%
—
—
—
—
—
—
—
—
—
—
cases:3.23%
controls:3.26%
7
55
227
2285
—
—
—
—
—
5
60
150
1781
Contusion of eyelid and periocular area
S00.1 [45553759]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
0
5
155
1836
Open wound of other parts of lower leg
S81.8 [45564809]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
0
6
155
1835
diltiazem; oral
C08DB01 [21601771]
—
—
—
—
-1.0e+50
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
cases:0.00%
controls:0.80%
cases:0.00%
controls:0.92%
—
—
—
—
0
10
229
2325
0
18
211
2234
0
17
155
1824
Block dissection of inguinal lymph nodes
PJD55 [2001309641]
—
—
—
—
1.0e+50
1.0e+50
—
—
—
—
—
—
—
—
—
cases:3.06%
controls:0.00%
cases:15.64%
controls:0.00%
—
—
—
—
—
—
7
0
222
2335
33
0
178
2252
—
Emergency visit or other similar visit involving procedures
WYA05 [2001310871]
1.3e-01
-1.0e+50
-1.0e+50
—
—
-1.0e+50
—
cases:10.26%
controls:9.15%
cases:0.00%
controls:2.69%
cases:0.00%
controls:0.26%
—
—
—
—
cases:0.00%
controls:2.13%
—
—
24
214
210
2126
0
63
233
2277
0
6
233
2334
—
—
0
48
211
2204
—
Metatarsalgia
M77.4 [45601544]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
234
2333
—
—
—
—
—
—
Other function in accordance with podiatry nomenclature
SPAT1299 [2001700400]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
0
8
234
2332
—
—
—
—
—
0
5
155
1836
Breathalyser test
225622001 [4023193]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.21%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
234
2335
—
—
—
—
—
—
Perimetry
XCK00 [2001301380]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
cases:0.00%
controls:0.98%
—
—
—
—
—
0
6
211
2246
0
18
155
1823
Contusion of abdominal wall
S30.1 [45602317]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
0
5
155
1836
Senile macular degeneration (atrophic)(exudative)
H35.31 [2000502315]
-1.0e+50
-1.0e+50
-1.0e+50
—
-1.0e+50
-1.0e+50
—
cases:0.00%
controls:0.77%
cases:0.00%
controls:0.73%
cases:0.00%
controls:0.43%
—
—
cases:0.00%
controls:0.34%
cases:0.00%
controls:0.80%
—
—
0
18
234
2322
0
17
233
2323
0
10
233
2330
—
0
8
229
2327
0
18
211
2234
—
perindopril; oral
C09AA04 [21601788]
—
-1.0e+50
-1.0e+50
—
-1.0e+50
—
—
—
—
cases:0.00%
controls:0.94%
cases:0.00%
controls:0.21%
—
—
cases:0.00%
controls:0.26%
—
—
—
—
—
0
22
233
2318
0
5
233
2335
—
0
6
229
2329
—
—
chlorphenamine, combinations
R06AB54 [21603468]
7.4e-01
—
—
—
—
—
—
cases:2.99%
controls:1.45%
—
—
—
—
—
—
—
—
—
—
—
—
7
34
227
2306
—
—
—
—
—
—
dexamethasone
C05AA09 [21601613]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
—
0
7
233
2333
—
—
—
—
—
amoxicillin and beta-lactamase inhibitor; oral, parenteral
J01CR02 [21602863]
4.5e-01
8.6e-01
—
—
2.0e+00
8.3e-01
3.8e-01
cases:11.11%
controls:7.39%
cases:3.86%
controls:1.67%
—
—
—
—
cases:2.18%
controls:0.30%
cases:4.27%
controls:1.91%
cases:10.97%
controls:7.77%
26
173
208
2167
9
39
224
2301
—
—
5
7
224
2328
9
43
202
2209
17
143
138
1698
Catheterization of the left side of the heart
AP1 [2000200175]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
234
2332
—
—
—
—
—
—
Knee symptom/complaint
L15 [2002000639]
-1.1e-01
—
-1.0e+50
—
—
—
—
cases:2.56%
controls:2.86%
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
6
67
228
2273
—
0
7
233
2333
—
—
—
—
Lumbar spine MRI examination with high intensity magnet
NA3BG [2001307034]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.98%
cases:0.00%
controls:0.21%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.03%
0
23
234
2317
0
5
233
2335
—
—
—
—
0
19
155
1822
metoprolol; oral, parenteral
C07AB02 [21601684]
-3.6e-01
-2.5e-03
—
—
—
-1.9e-01
-2.4e-01
cases:5.56%
controls:7.78%
cases:6.44%
controls:6.45%
—
—
—
—
—
—
cases:5.21%
controls:6.22%
cases:6.45%
controls:8.04%
13
182
221
2158
15
151
218
2189
—
—
—
11
140
200
2112
10
148
145
1693
Inflammatory disease of prostate, unspecified
N41.9 [45539049]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
0
6
155
1835
Bordetella pertussis IgA Ab [Units/volume] in Serum
9362-5 [3025149]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.21%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
234
2335
—
—
—
—
—
—
glyceryl trinitrate; local oral, oral, sublingual, transdermal
C01DA02 [21600317]
-2.4e-01
-4.7e-01
—
—
—
-4.1e-01
-2.0e-01
cases:6.84%
controls:8.55%
cases:3.00%
controls:4.70%
—
—
—
—
—
—
cases:3.32%
controls:4.93%
cases:7.74%
controls:9.29%
16
200
218
2140
7
110
226
2230
—
—
—
7
111
204
2141
12
171
143
1670
Heart failure, unspecified
I50.9 [45576879]
-2.9e-02
4.6e-01
—
—
—
4.8e-01
—
cases:2.99%
controls:3.08%
cases:2.15%
controls:1.37%
—
—
—
—
—
—
cases:3.32%
controls:2.09%
—
—
7
72
227
2268
5
32
228
2308
—
—
—
7
47
204
2205
—
Resection of lax skin in upper eyelid
CBB11 [2001300924]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
0
8
155
1833
Electrocardiogram with exercise test
46136006 [4261794]
3.5e-01
—
—
—
—
—
—
cases:2.99%
controls:2.14%
—
—
—
—
—
—
—
—
—
—
—
—
7
50
227
2290
—
—
—
—
—
—
flecainide; oral, parenteral
C01BC04 [21600266]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.26%
—
—
—
—
—
—
—
—
0
6
229
2329
—
—
Triglyceride [Moles/volume] in Serum or Plasma --fasting
47210-0 [3048773]
7.2e-02
7.4e-02
8.6e-01
—
—
-2.4e-01
4.4e-02
cases:31.62%
controls:30.09%
cases:18.88%
controls:17.78%
cases:3.86%
controls:1.67%
—
—
—
—
cases:13.74%
controls:16.83%
cases:40.65%
controls:39.60%
74
704
160
1636
44
416
189
1924
9
39
224
2301
—
—
29
379
182
1873
63
729
92
1112
Demanding periodontal treatment
SDA04 [2001310329]
1.6e-01
—
—
—
-1.0e+50
—
-6.9e-01
cases:4.27%
controls:3.68%
—
—
—
—
—
—
cases:0.00%
controls:0.26%
—
—
cases:3.23%
controls:6.25%
10
86
224
2254
—
—
—
0
6
229
2329
—
5
115
150
1726
Parkinson's disease and comparable movement disrorders
110 [2001600110]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
0
6
155
1835
buprenorphine; parenteral, sublingual, transdermal
N02AE01 [21604287]
—
—
—
—
—
6.8e-01
6.0e-01
—
—
—
—
—
—
—
—
—
—
cases:2.84%
controls:1.47%
cases:6.45%
controls:3.64%
—
—
—
—
—
6
33
205
2219
10
67
145
1774
Laparoscopic repair of inguinal hernia, TEP
JAB12 [2001304391]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.21%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
234
2335
—
—
—
—
—
—
lovastatin; oral
C10AA02 [21601857]
-1.0e+50
-1.0e+50
—
—
-1.0e+50
-1.0e+50
—
cases:0.00%
controls:0.94%
cases:0.00%
controls:0.90%
—
—
—
—
cases:0.00%
controls:0.39%
cases:0.00%
controls:0.93%
—
—
0
22
234
2318
0
21
233
2319
—
—
0
9
229
2326
0
21
211
2231
—
Voluntary or Charitable Agency
251V00000X [38004202]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.22%
—
—
—
—
—
—
—
0
5
211
2247
—
Medical Oncology
90 [38004507]
—
1.0e+50
1.0e+50
1.0e+50
1.0e+50
1.0e+50
—
—
—
cases:9.87%
controls:0.00%
cases:4.72%
controls:0.00%
cases:3.86%
controls:0.00%
cases:8.30%
controls:0.00%
cases:25.12%
controls:0.00%
—
—
—
23
0
210
2340
11
0
222
2340
9
0
224
2340
19
0
210
2335
53
0
158
2252
—
Hemolysis interference index of Serum or Plasma
46424-8 [3052851]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
cases:0.00%
controls:0.40%
cases:0.00%
controls:0.43%
—
0
8
233
2332
—
—
—
0
9
211
2243
0
8
155
1833
Alkaline phosphatase.intestinal [Enzymatic activity/volume] in Serum or Plasma
1778-0 [3020013]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.21%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
234
2335
—
—
—
—
—
—
bromfenac
S01BC11 [21603649]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.21%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.54%
0
5
234
2335
—
—
—
—
—
0
10
155
1831
Release of median nerve
ACC51 [2001300642]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
234
2330
—
—
—
—
—
—
Ammonium ion [Moles/volume] in Plasma
1845-7 [3023183]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
234
2332
—
—
—
—
—
—
MRI examination of lower part of abdoment with high intensity magnet
JN2BG [2001305540]
—
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:2.18%
controls:0.00%
—
—
—
—
—
—
—
—
5
0
224
2335
—
—
misoprostol; oral
A02BB01 [21600093]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
0
6
155
1835
Screening of depression or other psychiatric problem
SPAT1246 [2001700347]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.21%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
234
2335
—
—
—
—
—
—
Phlebitis/thrombophlebitis
K94 [2002000621]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.26%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
0
6
234
2334
—
—
—
—
—
0
7
155
1834
Smith extractable nuclear Ab [Units/volume] in Serum
11090-8 [3016921]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.21%
—
—
—
—
—
—
—
—
—
—
—
0
5
233
2335
—
—
—
—
—
Rehabilitation Hospital
283X00000X [38004285]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.73%
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
0
17
234
2323
0
7
233
2333
—
—
—
—
—
Unilateral or unspecified inguinal hernia, with obstruction, without gangrene
K40.3 [45543306]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
0
5
155
1836
Left bundle-branch block, unspecified
I44.7 [45586583]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
0
6
155
1835
Snapping jaw
K07.60 [2000502791]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
0
5
155
1836
metformin and rosiglitazone
A10BD03 [21600768]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.21%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
234
2335
—
—
—
—
—
—
Iron deficiency anaemia
D50 [45571628]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.21%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
234
2335
—
—
—
—
—
—
Bacteria identified in Stool by Culture
625-4 [3025941]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
0
16
234
2324
—
—
—
—
0
6
211
2246
—
Mycobacterium sp identified in Specimen by Organism specific culture
543-9 [3005702]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
—
0
7
233
2333
—
—
—
—
—
Neoplasm of uncertain or unknown behaviour: Other male genital organs
D40.7 [45532983]
—
1.0e+50
1.0e+50
1.0e+50
1.0e+50
1.0e+50
1.0e+50
—
—
cases:2.58%
controls:0.00%
cases:7.73%
controls:0.00%
cases:8.15%
controls:0.00%
cases:8.73%
controls:0.00%
cases:5.21%
controls:0.00%
cases:3.23%
controls:0.00%
—
6
0
227
2340
18
0
215
2340
19
0
214
2340
20
0
209
2335
11
0
200
2252
5
0
150
1841
Collection duration of Urine
13362-9 [3016750]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
0
9
155
1832
Acute conjunctivitis, unspecified
H10.3 [45566958]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
—
—
—
—
—
0
14
234
2326
—
—
—
—
—
—
clobetasol
D07AD01 [21602141]
2.7e-01
1.6e+00
—
—
—
1.6e+00
9.5e-01
cases:2.99%
controls:2.31%
cases:3.43%
controls:0.73%
—
—
—
—
—
—
cases:2.37%
controls:0.49%
cases:6.45%
controls:2.61%
7
54
227
2286
8
17
225
2323
—
—
—
5
11
206
2241
10
48
145
1793
Mucosa-supported partial denture
SPE01 [2001310537]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.21%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
234
2335
—
—
—
—
—
—
Hypertension uncomplicated
K86 [2002000613]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.90%
—
—
—
—
—
—
—
—
—
—
—
0
21
233
2319
—
—
—
—
—
Dental calculus supragingival
K03.64 [2000502689]
—
—
-1.0e+50
—
—
—
7.5e-01
—
—
—
—
cases:0.00%
controls:0.21%
—
—
—
—
—
—
cases:8.39%
controls:4.13%
—
—
0
5
233
2335
—
—
—
13
76
142
1765
Influenza due to identified zoonotic or pandemic influenza virus
J09 [45755449]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.21%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
0
5
234
2335
—
—
—
—
—
0
7
155
1834
Bronchiectasis
J47 [45605889]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.34%
cases:0.00%
controls:0.21%
—
—
—
—
—
—
—
—
—
—
0
8
234
2332
0
5
233
2335
—
—
—
—
—
pioglitazone; oral
A10BG03 [21600782]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
0
9
233
2331
—
—
—
0
8
211
2244
—
Impacted cerumen
H61.2 [45562307]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
—
0
9
211
2243
—
Varicose veins of lower extremities with ulcer
I83.0 [45557601]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.26%
—
—
—
—
—
—
cases:0.00%
controls:0.22%
—
—
—
0
6
233
2334
—
—
—
0
5
211
2247
—
Prostate specific Ag panel - Serum or Plasma
53764-7 [3039443]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
—
0
9
211
2243
—
ketoconazole
D01AC08 [21601927]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.21%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
234
2335
—
—
—
—
—
—
Calculus of bile duct without cholangitis or cholecystitis
K80.5 [45572234]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
0
6
155
1835
General and Unspecified, Other reason for encounter NEC
A69 [2002000203]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
0
11
155
1830
Operation on infrarenal abdominal aorta for aneurysm
PDG05 [2001309134]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.21%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
234
2335
—
—
—
—
—
—

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
68
41
22.89
84.85
1.8
1.2
—
—
—
0
0
74
121
8.45
46.58
1.5
1.1
—
—
—
0
0
126
419
5.31
36.41
3.5
1.6
—
—
—
0
0
156
738
4.29
25.83
4.1
2.4
—
—
estimate
—
0
0
108
410
4.01
24.24
3.6
3.0
—
—
—
0
0
72
212
4.45
22.78
2.2
1.8
—
—
—
0
0
122
535
3.65
21.52
3.1
2.1
—
—
—
0
0
34
55
7.05
20.82
2.1
1.2
—
—
—
0
0
180
1061
3.94
19.10
7.0
3.9
18.43
367.06
e6/l
—
7
17
71
283
3.16
13.61
2.6
1.9
—
—
—
0
0
111
567
2.81
13.51
6.8
3.9
—
—
—
0
0
106
588
2.46
10.22
5.0
2.9
32.64
186.31
e6/l
0.76
86
448
86
439
2.51
9.87
1.6
1.3
—
—
—
0
0
110
637
2.36
9.45
5.7
3.3
596.98
92.80
e6/l
0.53
89
458
182
1316
2.67
9.42
14.2
5.8
84.71
77.50
u/l
1.29
173
1228
136
871
2.32
9.13
10.6
6.6
1.19
1.20
mmol/l
0.62
115
748
29
85
3.75
8.82
2.2
1.7
2.42
2.46
ug/l
0.01
22
75
87
466
2.37
8.81
4.2
2.6
—
0.00
estimate
—
0
6
144
958
2.29
8.66
16.0
19.0
1.25
1.38
inr
2.25
123
802
123
777
2.22
8.27
8.5
3.9
34.17
35.46
g/l
1.83
115
717
90
504
2.27
8.10
4.5
2.7
0.37
0.34
e6/l
0.09
70
368
95
548
2.23
7.92
9.1
5.2
—
—
—
0
0
39
150
2.92
7.67
1.6
1.4
—
—
—
0
0
24
68
3.82
7.64
3.5
1.7
—
—
—
0
0
121
777
2.14
7.61
9.8
6.2
1.19
1.19
mmol/l
0.45
113
703
136
916
2.14
7.53
17.4
6.3
4.35
4.51
e9/l
0.31
123
802
60
294
2.40
7.26
4.5
2.7
0.79
0.50
e6/l
0.51
36
153
44
196
2.53
6.49
1.5
1.7
—
—
—
0
0
82
479
2.09
6.38
7.7
3.8
7.40
7.40
ph
0.36
63
347
57
296
2.22
5.93
8.1
6.3
105.26
104.34
mmol/l
1.12
57
296
24
84
3.07
5.54
1.4
1.6
—
—
—
0
0
85
525
1.97
5.54
7.4
2.0
2.35
2.33
mmol/l
0.58
77
444
112
765
1.88
5.35
10.1
5.7
9.16
9.30
%
0.18
107
715
125
885
1.88
5.33
5.1
3.5
0.00
0.03
estimate
0.50
31
154
63
355
2.06
5.27
3.8
2.5
562.33
581.58
mosm/kgh2o
0.28
57
298
103
688
1.88
5.24
4.4
3.2
6.14
6.18
ph
0.12
69
395
123
870
1.86
5.22
5.1
3.5
45.43
0.00
estimate
0.49
35
171
122
861
1.86
5.22
5.1
3.5
0.00
0.00
estimate
-0.00
31
171
76
460
1.96
5.20
4.7
3.0
0.00
0.00
estimate
-0.00
20
125
111
762
1.86
5.17
10.2
5.7
3.05
3.21
%
0.20
106
715
113
781
1.86
5.14
10.1
5.8
23.01
25.32
%
1.10
108
741
34
151
2.46
5.02
1.9
1.6
—
—
—
0
0
111
769
1.84
4.96
10.3
5.7
0.61
0.65
%
0.43
106
724
8
10
8.23
4.09
2.6
2.7
609.00
1414.10
e6/l
—
8
10
33
162
2.21
3.89
6.1
3.4
7.37
7.34
ph
0.48
27
110
105
765
1.67
3.62
22.6
10.3
0.00
0.00
e9/l
0.72
88
633
115
860
1.66
3.57
9.9
5.7
1.79
1.78
e9/l
0.01
102
755
197
1710
1.92
3.46
33.0
15.3
35.23
28.19
mg/l
1.78
185
1390
113
849
1.64
3.40
10.0
5.6
0.66
0.64
e9/l
0.36
97
730
113
850
1.63
3.38
9.9
5.6
0.04
0.04
e9/l
0.10
96
736
34
180
2.04
3.31
10.0
8.7
—
—
—
0
0
115
872
1.62
3.31
10.3
5.6
0.25
0.23
e9/l
0.24
101
760
6
7
8.75
3.28
3.0
1.3
54.83
189.43
e6/l
—
6
7
93
671
1.64
3.26
5.1
3.6
0.00
0.00
estimate
-0.00
26
136
6
8
7.66
3.07
1.8
2.3
30.18
46.44
%
—
6
8
28
143
2.09
3.00
4.1
4.6
0.00
0.03
%
0.49
13
31
43
257
1.82
2.94
5.6
1.8
1.69
1.70
%
0.01
43
223
56
362
1.72
2.94
2.4
1.8
1277.93
1187.82
nmol/l
0.22
45
281
7
13
5.51
2.89
1.0
1.2
—
—
—
0
0
52
334
1.71
2.79
6.4
2.0
2.50
2.43
mmol/l
2.80
46
288
12
42
2.95
2.59
4.0
4.2
—
—
—
0
0
5
7
7.27
2.56
1.4
3.6
69.60
70.57
%
—
5
7
5
7
7.27
2.56
1.4
1.1
—
—
—
0
0
27
145
1.97
2.54
3.6
4.3
0.92
0.68
%
0.28
12
40
7
16
4.47
2.49
1.0
1.2
—
—
—
0
0
66
467
1.57
2.40
9.4
4.6
—
—
—
0
0
26
141
1.95
2.39
3.7
4.4
0.18
0.11
%
0.15
11
36
5
8
6.35
2.38
3.4
2.9
346.80
570.63
e6/l
—
5
8
5
8
6.35
2.38
3.0
2.9
201.00
282.50
e6/l
—
5
8
160
1375
1.51
2.25
36.4
18.3
14.25
13.67
%
4.59
160
1353
13
54
2.49
2.24
3.3
1.2
1.31
1.49
ratio
—
6
33
69
504
1.52
2.16
2.4
2.2
3.20
2.82
mg/l
0.56
59
423
35
216
1.73
2.16
1.9
1.4
—
—
—
0
0
25
140
1.88
2.11
3.1
4.2
0.82
0.34
%
0.47
11
38
9
31
2.98
2.09
1.9
1.3
—
—
—
0
0
5
10
5.08
2.08
1.2
1.1
18.02
28.90
ng/l
—
5
10
5
10
5.08
2.08
3.4
2.1
0.40
0.93
e9/l
—
5
10
38
243
1.67
2.06
8.4
7.5
91.28
94.36
%
0.84
38
238
7
21
3.40
1.98
1.1
1.2
—
—
—
0
0
8
27
3.03
1.95
1.5
1.3
—
—
—
0
0
5
11
4.62
1.95
1.0
1.0
—
—
—
0
0
6
16
3.82
1.94
1.3
1.3
—
—
—
0
0
7
22
3.25
1.89
1.3
1.1
—
—
—
0
0
21
116
1.89
1.85
2.4
1.3
—
—
—
0
0
8
29
2.82
1.81
2.0
1.4
32.00
34.31
pg
—
8
29
8
30
2.72
1.74
3.3
2.2
—
—
—
0
0
39
264
1.57
1.70
8.8
7.4
-0.06
0.88
mmol/l
0.62
34
212
8
31
2.63
1.67
1.3
1.2
32.41
25.96
g/l
—
8
26
66
502
1.44
1.66
5.6
3.5
0.00
0.02
estimate
0.50
27
154
5
14
3.62
1.62
1.2
1.1
—
—
—
0
0
74
578
1.41
1.60
1.8
1.7
16.73
18.13
nmol/l
0.48
66
487
31
202
1.62
1.58
4.5
1.9
63.64
64.48
e9/l
0.07
26
154
22
131
1.75
1.56
1.8
2.0
28.53
34.11
u/l
0.47
15
106
26
163
1.67
1.54
1.7
1.3
—
—
—
0
0
197
1819
1.50
1.52
17.7
10.2
26.96
28.78
u/l
0.72
187
1750
194
1786
1.48
1.52
27.4
14.1
—
—
—
0
0
159
1418
1.37
1.46
8.1
4.2
26.48
1.97
ug/l
0.65
148
1262
54
407
1.42
1.42
4.1
3.9
1.02
1.02
kg/l
0.37
48
259
5
123
0.39
1.41
3.4
2.0
39.40
41.58
nmol/l
—
5
116
7
29
2.46
1.40
2.3
2.6
1.18
1.19
mmol/l
—
7
29
90
743
1.34
1.36
3.8
2.8
224.16
187.26
ug/l
0.42
83
680
20
121
1.71
1.36
5.9
2.8
—
—
—
0
0
15
83
1.86
1.34
2.9
2.5
—
—
—
0
0
28
186
1.57
1.34
1.3
1.3
280.00
368.00
titre
—
6
45
38
272
1.47
1.30
8.8
7.3
7.41
7.41
ph
0.08
15
165
8
35
2.33
1.28
1.4
1.1
—
—
—
0
0
201
1882
1.46
1.25
46.9
23.0
7.40
6.90
e9/l
2.01
196
1830
12
63
1.95
1.25
6.5
2.6
267.29
328.04
mg/l
—
7
27
6
25
2.44
1.25
2.8
2.5
56.33
60.26
%
—
6
25
11
57
1.98
1.19
4.8
3.7
—
—
—
0
0
5
20
2.53
1.15
1.6
1.5
—
—
—
0
0
5
20
2.53
1.15
1.6
1.5
—
—
—
0
0
5
20
2.53
1.15
3.0
2.6
3.95
4.78
e9/l
—
5
20
5
20
2.53
1.15
1.6
1.5
—
—
—
0
0
5
20
2.53
1.15
1.6
1.5
—
—
—
0
0
16
96
1.72
1.13
4.9
3.3
1.02
1.02
ratio
0.02
16
91
7
31
2.30
1.11
2.3
2.5
105.43
104.94
mmol/l
—
7
31
7
31
2.30
1.11
2.3
2.5
3.93
4.18
mmol/l
—
7
31
12
66
1.86
1.11
1.2
1.8
—
—
—
0
0
5
21
2.41
1.09
1.4
1.6
8.14
8.47
mmol/l
—
5
21
85
716
1.29
1.07
4.8
4.0
—
—
—
0
0
129
1146
1.28
1.07
4.1
3.4
70.65
56.05
u/l
0.95
121
1071
12
67
1.83
1.06
1.7
1.7
—
—
—
0
0
102
881
1.28
1.06
2.3
2.1
91.72
91.77
pmol/l
0.00
64
502
5
106
0.46
1.04
1.8
2.0
219.20
221.71
pmol/l
—
5
99
5
22
2.30
1.04
1.0
2.0
—
4.46
—
0
12
24
165
1.51
1.01
8.1
3.8
7.42
7.41
ph
0.31
19
138
17
109
1.60
0.96
1.2
1.3
1246.18
485.57
u/ml
0.47
17
100
6
28
2.17
0.92
2.8
3.3
—
—
—
0
0
6
28
2.17
0.92
2.3
2.1
2.70
1.48
g/24h
—
6
17
29
212
1.42
0.92
1.2
1.2
—
—
—
0
0
15
228
0.63
0.91
1.9
2.9
9.46
9.19
ug/l
—
10
198
8
43
1.89
0.88
1.0
1.1
—
—
—
0
0
0
25
0.00
0.79
0.0
1.1
—
—
—
0
0
31
237
1.35
0.77
4.2
3.4
7.38
7.38
ph
0.20
21
153
17
239
0.69
0.73
1.1
1.2
0.87
8.63
u/ml
—
7
85
46
377
1.27
0.71
1.4
1.6
1.43
1.22
mg/l
0.24
39
291
63
537
1.24
0.70
3.7
2.7
390.23
383.81
umol/l
0.21
57
471
7
41
1.73
0.70
3.7
4.0
62.29
24.58
mg/l
—
7
36
22
163
1.39
0.67
2.5
1.5
—
—
—
0
0
95
850
1.20
0.65
5.0
4.3
38.35
48.60
ng/l
0.60
82
661
17
121
1.44
0.64
9.9
4.0
—
—
—
0
0
0
21
0.00
0.60
0.0
1.3
—
—
—
0
0
178
1701
1.19
0.51
5.2
5.5
6.29
6.19
mmol/l
0.50
162
1531
27
220
1.26
0.46
2.6
2.7
4.00
4.77
e9/l
0.62
22
188
33
276
1.23
0.45
2.2
1.3
3.13
3.10
g/l
0.02
24
177
7
50
1.41
0.45
1.4
1.1
1.34
1.43
g/l
—
7
50
0
15
0.00
0.41
0.0
1.5
—
86.13
—
0
15
0
16
0.00
0.41
0.0
1.0
—
224.91
—
0
11
41
355
1.19
0.41
7.0
4.4
—
—
—
0
0
6
87
0.68
0.33
2.0
1.7
—
—
—
0
0
62
675
0.89
0.30
3.4
3.5
—
—
—
0
0
46
414
1.14
0.29
4.4
4.2
288.16
528.44
ng/l
0.51
37
348
86
807
1.10
0.27
3.7
2.9
1.00
0.78
ug/l
0.46
59
524
5
41
1.22
0.22
1.2
1.3
0.92
0.83
nmol/l
—
5
34
5
41
1.22
0.22
1.4
1.3
—
—
—
0
0
12
98
1.24
0.21
1.2
1.3
—
—
—
0
0
0
10
0.00
0.21
0.0
1.3
—
—
—
0
0
0
10
0.00
0.21
0.0
16.0
—
1602.40
—
0
10
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.1
—
27.18
—
0
13
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
23
260
0.87
0.20
1.1
1.2
12.84
28.62
iu/ml
—
5
72
0
14
0.00
0.20
0.0
2.0
—
4.22
—
0
14
28
311
0.89
0.19
1.1
1.3
0.76
1.35
u/ml
—
5
93
13
151
0.85
0.16
5.2
4.5
—
—
—
0
0
7
87
0.80
0.15
1.0
1.1
—
—
—
0
0
173
1761
0.93
0.14
5.4
6.3
2.49
2.51
mmol/l
0.09
155
1621
5
45
1.11
0.10
1.8
3.2
0.60
0.96
nmol/l
—
5
37
6
55
1.09
0.09
1.0
1.1
—
0.26
—
0
5
70
722
0.96
0.08
2.0
2.0
1.72
1.35
mmol/l
2.20
56
600
164
1660
0.96
0.07
4.7
4.6
1.48
1.32
mmol/l
2.14
145
1506
119
1170
1.03
0.07
3.3
3.1
14.55
15.02
pmol/l
1.35
108
1046
77
755
1.03
0.05
4.8
4.3
15.05
10.14
mg/mmol
0.40
55
523
74
754
0.97
0.04
3.9
3.5
7.65
8.66
mmol/l
1.34
63
649
170
1713
0.97
0.04
5.0
5.5
1.24
1.31
mmol/l
1.59
148
1566
170
1687
1.03
0.04
7.1
7.5
41.21
40.83
mmol/mol
0.21
151
1563
72
732
0.98
0.03
4.1
3.6
99.69
63.40
mg/l
0.45
53
518
11
118
0.93
0.03
3.3
2.3
0.65
0.62
%
0.10
11
118
12
121
0.99
0.00
3.6
2.4
1.19
1.15
%
0.03
12
121
154
1544
0.99
0.00
4.1
4.1
1.93
2.03
mu/l
0.46
136
1378
172
1722
1.00
0.00
5.3
5.6
4.37
4.29
mmol/l
0.41
152
1588
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
11.0
—
0.53
—
0
6
0
5
0.00
-0.00
0.0
1.0
—
0.00
—
0
5
0
5
0.00
-0.00
0.0
2.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
17.14
—
0
5
0
9
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
6
0.00
-0.00
0.0
8.5
—
8.03
—
0
6
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0

Mortality – FinRegistry

↥

This endpoint is excluded (different definition than used in FinnGen).

Relationships between endpoints

↥

Index endpoint: C3_PENIS_WIDE – Malignant neoplasm of penis, including Hilmo

GWS hits: -

This endpoint is excluded (different definition than used in FinnGen).